Recombinant Plasmodium Falciparum Merozoite Surface Proteins 4 and 5 and Their Use

ABSTRACT

Accordingly, the invention provides constructs in which the nucleic acids encoding  Plasmodium falciparum  MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.

This application relates to recombinant Plasmodium Falciparum MerozoiteSurface Proteins 4 and 5 and to theirs use.

FIELD OF THE INVENTION

This invention is directed to recombinant isolated polypeptides, thenucleic acids encoding such polypeptides, processes for production ofrecombinant forms of such polypeptides, antibodies generated againstthese polypeptides, and the use of such polypeptides and antibodies indiagnostic methods, kits, vaccines, or anti-parasite therapy.

BACKGROUND OF THE INVENTION

Malaria is responsible for approximately 2 million deaths per yearworldwide, mostly African children under 5 years old, and places anenormous public health burden on many of the world's poorest countries.This burden is increasing at an alarming rate, as drug resistance inboth the parasite and its mosquito vectors spreads, exacerbating theurgent need for an effective vaccine.

The most promising blood stage vaccine candidates examined so far aremerozoite surface protein 1 (MSP1) and an apical membrane antigen(AMA1). Humoral immune responses targeting these surface antigens arefound to be correlated with reduced disease incidence, and in vitro,such antibodies can inhibit parasite re-invasion of red blood cells(RBC) [1-3]. However, these antigen genes generally display adisproportionately high number of non-synonymous single nucleotidepolymorphisms (nsSNPs) compared to genes coding for proteins that arenot accessible to immune effectors [4-6], and some of these nsSNPsencode radical amino acid substitutions that clustered within theregions of the protein most accessible to the host immune system [7].Such amino acid polymorphisms could function in immune evasion byaltering both B and T cell epitopes [4,8]. It is now generally acceptedthat any functional malaria vaccine will need to be composed of severalallelic types of each target antigen in the hope of inducing amulti-allelic response and/or conserved regions of several targetantigens.

More particularly, there exists a need in the art for antigens that canbe used in the diagnosis and treatment of malaria and in particular ofPlasmodium falciparum malaria and Plasmodium vivax malaria. Inparticular, there is a need for conserved antigens associated withspecific immune responses that confer protection from disease in endemicregions, and the assessment of their suitability as components of amulti-valiant malaria vaccine.

SUMMARY OF THE INVENTION

This invention aids in fulfilling these needs in the art. The inventionprovides a purified or recombinant or synthetic nucleic acid moleculecomprising a DNA sequence of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, or 8 and apurified or recombinant or synthetic nucleic acid molecule encoding theamino acid sequence of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, or 22. The invention also encompasses purified nucleicacid molecules complementary to these sequences.

The invention also encompasses purified polypeptides encoded by thepurified or recombinant nucleic acid molecules comprising a DNA sequenceof SEQ ID NOS: 1-8, as predicted by the sequence.

Reference to a DNA sequence of SEQ ID NOs: 1-8 or to an amino acidsequence of SEQ ID Nos. 9-22 is a reference to any and each of thesesequences.

The invention includes purified double-stranded nucleic acid moleculescomprising the DNA sequence of SEQ ID NOS: 1-8, and purifieddouble-stranded nucleic acid molecules encoding the amino acid sequenceof SEQ ID NOS: 9-22. Both single-stranded and double-stranded RNA andDNA nucleic acid molecules are encompassed by the invention. Thesemolecules can be used to detect both single-stranded and double-strandedRNA and DNA variants encoding polypeptides encompassed by the invention.A double-stranded DNA probe allows the detection of nucleic acidmolecules equivalent to either strand of the nucleic acid molecule.

Purified nucleic acid molecules that hybridize to a denatured,double-stranded DNA comprising the DNA sequence of SEQ ID NOS: 1-8, andencoding the amino acid sequence of SEQ ID NOS: 9-22 under conditions ofmoderate stringency in 50% formamide and 6×SSC, at 42° C. with washingconditions of 60° C., 0.5×SSC, 0.1% SDS are encompassed by theinvention.

The invention further encompasses purified nucleic acid moleculesderived by in vitro mutagenesis from SEQ ID NOS: 1-8. In vitromutagenesis includes numerous techniques known in the art including, butnot limited to, site-directed mutagenesis, random mutagenesis, and invitro nucleic acid synthesis. Such nucleic acid molecules derived by invitro mutagenesis from the cited sequences, are according to aparticular embodiment, of the same length or have a shorter sequencethan the original one.

The nucleic acid molecules of the invention, which include DNA and RNA,are referred to herein as “recombinant MSP4 and MSP5 nucleic acids” or“recombinant MSP4 and MSP5 DNA”, and the amino acids encoded by thesemolecules are referred to herein as “recombinant MSP4 and MSP5polypeptides” or “the polypeptides of the invention”.

The invention also encompasses purified nucleic acid moleculesdegenerate from SEQ ID NOS: 1-8 as a result of the genetic code,purified nucleic acid molecules, which are allelic variants ofrecombinant MSP4 and MSP5 nucleic acids, or a species homolog ofrecombinant MSP4 and MSP5 nucleic acids. The invention also encompassesrecombinant vectors that direct the expression of these nucleic acidmolecules and host cells transformed, transfected or infected with thesevectors.

Purified polyclonal or monoclonal antibodies that bind to recombinantMSP4 or MSP5 polypeptides are encompassed by the invention and arereferred to herein as “the antibodies of the invention”.

The invention further encompasses methods for the production ofrecombinant MSP4 and MSP5 polypeptides, including culturing a host cellunder conditions promoting expression, and recovering the polypeptidefrom the culture medium or cellular pellets. Especially, the expressionof recombinant MSP4 and MSP5 polypeptides in baculovirus insectexpression systems is encompassed by the invention.

This invention also provides labelled recombinant MSP4 and MSP5polypeptides. Preferably, the labelled polypeptides are in purifiedform. It is also preferred that the unlabelled or labelled polypeptideis capable of being immunologically recognized by human body fluidcontaining antibodies to malaria. The polypeptides can be labelled, forexample, with an immunoassay label selected from the group consisting ofradioactive, enzymatic, fluorescent, chemiluminescent labels, andchromophores.

Immunological complexes between the recombinant MSP4 or MSP5polypeptides of the invention and antibodies recognizing those are alsoprovided. The immunological complexes can be labelled with animmunoassay label selected from the group consisting of radioactive,enzymatic, fluorescent, chemiluminescent labels, and chromophores.

Furthermore, this invention provides an in vitro method for detectingMSP4 and/or MSP5 polypeptides of a Plasmodium parasite. The methodcomprises providing a composition comprising a biological materialsuspected of containing MSP4 and/or MSP5 polypeptides of a Plasmodiumparasite (malaria parasite), and assaying for the presence of MSP4and/or MSP5 polypeptides of a Plasmodium parasite. The MSP4 and MSP5polypeptides of a Plasmodium parasite are typically assayed byelectrophoresis or by immunoassay with the antibodies of the invention.This method can be used for the detection of Plasmodium parasites in abiological sample, and in a preferred embodiment for detection ofPlasmodium falciparum and Plasmodium vivax parasites.

This invention also provides an in vitro diagnostic method for thedetection of the presence or absence of antibodies, which bind to anantigen comprising the recombinant or purified MSP4 or MSP5 polypeptidesof the invention or mixtures thereof. The method comprises contactingthe antigen with a biological fluid for a time and under conditionssufficient for the antigen and antibodies in the biological fluid toform an antigen-antibody complex, and then detecting the formation ofthe complex. The detection step can further comprise measuring theformation of the antigen-antibody complex. The formation of theantigen-antibody complex is preferably measured by immunoassay based onWestern blot technique, ELISA (enzyme linked immunosorbent assay),indirect immunofluorescent assay, or immunoprecipitation assay. Thismethod can be used for the detection of an immunological response to aPlasmodium parasite in a biological fluid coming from an animal or ahuman patient malaria infected. In a preferred embodiment this methodcan be used for the detection of an immunological response to aPlasmodium falciparum infection or a Plasmodium vivax infection.

A diagnostic kit for the detection of the presence or absence ofantibodies, which bind to the recombinant MSP4 or MSP5 polypeptides ofthe invention or mixtures thereof, contains antigen comprising therecombinant MSP4 and/or MSP5 polypeptides, or mixtures thereof, andmeans for detecting the formation of immune complexes between theantigen and antibodies. The antigen and the means are present in anamount sufficient to perform the detection.

A diagnostic kit for the detection of the presence or absence of MSP4and/or MSP5 polypeptides of Plasmodium parasite, contains the antibodiesof the invention, and means for detecting the formation of immunecomplexes between an antigen and the antibodies. The antibodies and themeans are present in an amount sufficient to perform the detection.

This invention also provides an immunogenic composition comprising arecombinant MSP4 or MSP5 polypeptide of the invention or a mixturethereof in an amount sufficient to induce an immunogenic or protectiveresponse in vivo, in association with a pharmaceutically acceptableimmunostimulator therefore. A vaccine composition of the inventioncomprises a sufficient amount of the recombinant MSP4 and/or MSP5polypeptide and a pharmaceutically acceptable immunostimulator thereforeto induce neutralizing antibodies.

The MSP4 and MSP5 polypeptides of the invention are thus useful as aportion of a diagnostic composition for detecting the presence ofantibodies to antigenic proteins associated with malaria.

In addition, the recombinant MSP4 and MSP5 polypeptides can be used toraise antibodies for detecting the presence of antigenic proteinsassociated with malaria.

The polypeptides of the invention can be also employed to raiseneutralizing antibodies that either inactivate the parasite, reduce theviability of the parasite in vivo, or inhibit or prevent parasitereplication. The ability to elicit parasite-neutralizing antibodies isespecially important when the polypeptides of the invention are used inimmunizing or vaccinating compositions.

Following is a vaccine, which includes (A) the natural signal sequence(B) a C-terminal His tag and (C) the acid repeat region that resemblesthat of the P. falciparum antigen most strongly correlated withprotective antibody responses in the field (MSP4p20).

[SEQ ID NO: 30] MKVAYFLSVLDLLIIFSLYFDGRRSAFAGIAACIRHGRILGEGGE/QNSTPGSGGQTGDHSAEAENGDYNEQGDDHGDDHGDDHGDDHGDEQDGEDYDDAEDDDLYELSEVDENANLCLDNNGGCGDDKICENLGKGIVKCLCKPGYKLV GTECVEHHHHHH

BRIEF DESCRIPTION OF THE DRAWINGS

This invention will be described with reference to the drawings inwhich:

FIG. 1 depicts the genomic organization of the msp4 and msp5 gene locusin several different species of Plasmodium. Cross species conservationof these genes is indicative of a fundamental function.

FIG. 2 shows that the sequence of SALSA is 92% identical to MSP-4 ofPlasmodium falciparum (PfMSP4). The SALSA sequence is known to harbourboth B and T-cell epitopes. The PfMSP4 sequence is shown in Black andthe SALSA sequence is shown in Grey.

FIG. 3 shows the full synthetic gene sequence of PfMSP4. All sequenceshown in this Figure was present in oligonucleotides. The gene sequenceof PfMSP4 is coded by overlapping oligo-sequences numbered (1-38) andhighlighted by alternating BOLD and normal text. Restriction sites arenoted in lower case text.

FIG. 4 depicts PCR fabrication of the synthetic gene. A sample of the“Gene assembly reaction” (5 or 10 μL, lanes 1 and 2 respectively) andthe “Gene amplification reaction” (5 or 10 μL, lanes 3 and 4respectively) resolved on a 1% agarose gel, flanked and separated by DNAsize standards

FIG. 5 shows an alignment of the four different MSP4 constructsgenerated for recombinant protein expression in the baculovirus system.The putative signal sequence (predicted by presently availablealgorithms) is high-lighted in Grey, common polymorphic sites arehighlighted in BOLD type and the sites most likely to be under balancingselection and thus involved in immune evasion are marked with an *.

FIG. 6 shows the full synthetic gene sequence of MSP5 of Plasmodiumfalciparum (PfMSP5). All sequence shown in this figure was present inoligonucleotides. The gene sequence of PfMSP5 is coded by theoverlapping oligo-sequences numbered (1-38) and high-lighted byalternating BOLD type and normal text. Restriction sites are noted inlower case text.

FIG. 7 depicts PCR fabrication of the synthetic gene. A sample of the“Gene amplification reaction” (5 μL) resolved on a 1% agarose gel,flanked by DNA size standards.

FIG. 8 shows PfMSP4 expression over time in two different insect celllines. Percentage cell death was calculated by mixing cell suspensions1:1 with 4% trypan blue and counting total cells and blue cells againsta grid under a cover slip. Protein was purified from infected culture SNat 24, 30, 36, 42, 48, 54, 60 and 72 h post infection (lanes 1-8,respectively) and 20 uL of the eluted protein was resolved in 4-12%Bis-Tris gels (Invitrogen) and stained with SimplyBlue safe stain(Invitrogen). These protein species were not seen in uninfected cellculture (lane 9)

FIG. 9 is a sequence alignment highlighting the N-terminal sequences ofeach MSP4 product: p40, p30 and p20. The signal sequence identified inthis study is highlighted in Grey. The N-terminal sequence of eachproduct is shown in blue BOLD type.

FIG. 10 shows the hydrophobicity profile of approximately 80 amino acidsresidues centered around the reported signal cleavage sites for threeknown malaria antigens. The first residue of the mature protein isindicated by a black diamond. The profile of S-antigen signal sequencecleavage is comparable to that seen for MSP4 in the baculovirus system.

FIG. 11 shows PfMSP5 expression over time in two different insect celllines. Cell death was calculated by mixing cell suspensions 1:1 with 4%trypan blue and counting total cells and blue cells against a grid undera cover slip. Protein was purified from culture SN at 24, 30, 36, 42,48, 54, 60 and 72 h post infection (lanes 1-8, respectively) and 20 uLof the eluted protein was resolved in 4-12% Bis-Tris gels (Invitrogen)and stained with SimplyBlue safe stain (Invitrogen). These proteinspecies were not seen in uninfected cell culture (lane 9)

FIG. 12 relates to polyclonal antisera raised in Rabbits. ELISA endpointtitres of sera raised against (A) the full-length MSP4p40 (R6-7) and (B)the MSP4 breakdown product p20 (R8-9), analysed using native (NR) orirreversibly reduced (R) MSP4-p40, as the coating antigen. Serum R8loses over 50% binding activity when the MSP4 antigen is reduced.Pre-immune sera is marked as NEG. Panel (C) shows the titres ofanti-MSP5 sera (56-57) analysed using MSP5-p45 and p35 as the coatingantigen

FIG. 13 depicts the results obtained by probing parasite material withpolyclonal sera raised against the baculovirus expressed antigens andMSP4p40 affinity purified sera from either a pool of human sera fromDielmo or a pool of antiMSP4 rabbit sera. Asynchronously growingparasites were extracted from iRBC and crudely fractionated using theprotocol of Wang et al (2003) [9]. Each lane 1 of each immune-blot wasloaded with a non-reduced Triton X100 soluble parasite fraction, lane 2with a non-reduced membrane fraction, lane 3 with a reduced Triton X100soluble parasite fraction and lane 4 with a reduced membrane fraction(Panels A, B and D). Panel C shows IFA data obtained with air-dried P.falciparum infected RBC.

FIG. 14 shows the ELISA analysis of sera from 9 immune adults (18-49yrs) from Dielmo collected in 1990 at the peak of the rainy season.Plates were coated with MSP4p40 (A) or MSP5p45 and p35 (B).

FIG. 15 is an immune-blot of (A) recombinant MSP4 p40, p30 and p20(lanes 3, 2 and 1, respectively) using human immune sera fromindividuals No. 3 and 9. (B) Immune blot analysis of recombinant MSP5using human immune sera from individual No. 8.

The ELISA profile generated for each serum is shown above each blot inFIGS. 16A and 16B, which depict the Western blots for two monoclonalantibodies, mAb L11-16 and mAb F12-7, that specifically recognizeepitopes on PfMSP4, p40 and p20. Legend: nR=non reduced, R=reduced byinvitrogen commercial buffer, iR=irreversibly reduced by DTT andacrylamide.

FIGS. 17A and 17B depict dilution factor (x-axis) as a function of OD orabsorbance (y-axis) for the mAbs in FIGS. 16A and 16B, respectively.

FIGS. 18A and 18B depict the Western blots for two monoclonalantibodies, mAb G21-2 and mAb J18-4, that specifically recognizeepitopes on PfMSP5, p45 and p35. Legend: nR=non reduced, R=reduced byinvitrogen commercial buffer, iR=irreversibly reduced by DTT andacrylamide.

FIGS. 19A and 19B depict dilution factor (x-axis) and a function of ODor absorbance (y-axis) for the mAbs in FIGS. 18A and 18B, respectively.

FIG. 20A-B depict ELISA analysis performed to optimise the proteincoating concentration. Plates were coated overnight with 0.5 or 1 μg/mLof protein in PBS, adding 100 μL/well. Panel (A) shows data obtainedwith the three different MSP4 derived antigens, MSP4p40, MSP4p30 (herenamed MSP4p40/2) and MSP4p20. Panel (B) shows data obtained with MSP5,plotted with the MSP4p20 data from panel (A) to demonstrate thedifferent strength of the responses. Since the optical densitiesobserved were nearly identical using either concentration, the lowercoating concentration (0.5 μg/mL) was used in all subsequent analyses.

FIG. 21A-D depict ELISA analysis of control sera from naive individuals(naff), hyper immune adults (shi), and an individual from the Dielmocohort of 2005 (60605). Plates were coated with 0.5 μg/mL of MSP5 (A),MSP4p40 (B), MSP4p20 (C), and MSP4p30 (D), and reactions were carriedout at varying dilutions of the anti-sera (3-fold dilution series). Allantigens were recognised by immune sera and not by the malaria naivecontrol.

FIG. 22A-D depict antibody responses of individuals from the Ndiopcohort of 2000, stratified by age as those over and under 15 years ofage. Panel (A) shows ELISA data in the form of optical density for theantigens (left to right) MSP4p20, MSP4p40, MSP4p30, and MSP5. Panel (C)shows the same data in the form of OD ratio. Panel (B) individualantibody responses to MSP1p19 are plotted as OD ratio as a function ofage for the Ndiop 2000 cohort, while panel (D) shows the ELISA OD ratioobtained against MSP5 with the same sera.

FIG. 23 depicts variation in the recognition of MSP4 and its derivativesby sera from the Ndiop 2000 cohort. The left hand panel shows theaverage response plotted as OD ratio for MSP4p20, MSP4p40, and MSP4p30(equals MSP4md2). The right hand panel shows the upper and lowerquartiles and the data spread for the antibody responses to each MSP4antigen as a function of age.

FIG. 24 depicts antibody dependent monocyte mediated cytotoxicitymeasured as induced oxidative bursts in the presence of specific sera.Sera were divided into those giving an OD ratio above or below themedian response of the cohort. Panel (A) shows data from sera divided asa function of MSP5 reactivity (above or below an OD ratio of 2.4), andpanel (B) shows data from sera divided as a function of MSP4p40reactivity (above or below an OD ratio of 20). Their ability to inducean oxidative burst in the presence of PBMC (peripheral blood mononuclearcells) and P. falciparum merozoites was analysed usingchemiluminescence. In both groups, an increase in oxidative burst wasseen with individuals showing high OD ratio.

FIG. 25 depicts the antibody isotype profile for each antigen analysedusing IgG specific secondary antibody reagents. Isotype profiles areshow for MSP4p40 (panel A) and MSP5 (panel B). Data is plotted as afunction of age (above and below the age of 15).

FIG. 26 is an alignment of amino acid sequences of PfMSP4 and PvMSP4.Several features of the Pf sequence have been highlighted (i) thesecretory and GPI attachment signals are shown in green, (ii) thesequence known as SALSA is underlined, (iii) all negatively chargedresidues (D and E) are shown in red, and (iv) the PfMSP4p20 N-terminalsequence and important cysteine residues are highlighted blue.

FIG. 27 depicts Baculovirus PfMSP5. (A) Purified recombinant PfMSP5 wasmigrated on SDS-PAGE gels, transferred to nitrocellulose and probed withhuman immune sera. (B) PfMSP5 was expressed in the presence of tritiatedmyristic acid. Purified protein was migrated on SDS-PAGE gels, bluestain and autoradiography performed for 7 weeks.

FIG. 28 depicts PfMSP4 expression over time in the RBC stages. (A)Acetone fixed ring stage parasites and air dried late stages and freemerozoites were probed with monoclonal antibody G17.12, which isspecific for PfMSP1p19 or polyclonal rabbit sera affinity purifiedagainst recombinant PfMSP4p20 (Rp20). Antibody staining was revealedwith Alexa Fluor® 488 goat anti-mouse or anti-rabbit conjugatedantibodies and parasite DNA was stained with Hoechst 33342. (B) Westernblot analysis of parasite extract from mature schizonts (S), freemerozoites (M), and Rings (R), using affinity purified rabbit (Rp20) andHuman sera (1:1 Ndiop and Dielmo pools: Hp20).

FIG. 29 depicts the protein sequence encoded by constructs used forrecombinant PfMSP4 expression. Shows the constructs designed tofacilitate direct expression of PfMSP4p20. Construct names are listed tothe left of the sequence text, the N-terminal sequence of each secretedprotein is high-lighted in bold within the text, and the recombinantprotein name is listed on the right-hand side.

FIG. 30 depicts direct expression of PfMSP4p20 over time. Samples ofculture supernatant of PfMSP4p40, PfMSP4p21, PfMSP4p21ss1 orPfMSP4p21ss2 baculovirus infected insect cells were collected at 6 hrintervals between 24 and 66 hr post infection, dialysed, and batchpurified over TALON resin. Purified protein samples were resolved onNuPAGE 4-12% gradient gels, blue stained, and protein size is indicatedto the right. Approximate protein yields were calculated using the last130 mL of culture supernatant remaining at 66 h post infection. Proteinwas purified by IMAC and HPLC and the protein yield calculated using theBCA protein dosage kit (PIERCE).

FIG. 31 depicts protein sequence alignment of PfMSP4p40 and PvMSP4/His.Amino acid (single letter code) sequences of Baculovirus P. vivax MSP4and P. falciparum MSP4 expression constructs aligned using clustalx.Amino acid identity is denoted (*), conservative substitutions (:),semi-conservative substitutions (.), and radical changes with a blank.The N-terminal sequences identified are underlined and in bold.N-terminal sequences for different protein products are underlined andin bold.

FIG. 32 depicts PvMSP4/His expression over time. In brief, 8 mL samplesof spinner culture SN were collected at 6 hr intervals between 24 and 66hr post infection, dialysed, and batch purified over TALON resin.Purified protein samples were resolved on NuPAGE 4-12% gradient gels,stained with SimplyBlue SafeStain and protein size is indicated to theleft and right.

FIG. 33 depicts human immune sera reactivity to PvMSP4/His. (A) ELISAplates were coated with PvMSP4/His expressed in the Baculovirusexpression system. Three-fold dilution series or all 24 sera weretested. (B) In parallel, each dilution series was tested againstirreversibly reduced PvMSP4. This graph shows the OD at dilution 1/2700in the lower panel of each sera giving an OD above the negative controlagainst the native antigen. The upper panel shows the reduction in ODseen on antigen reduction at a 1/2700 sera dilution.

FIGS. 34 and 35 depicts the results of the treatment of sera(decomplemented, IgG depleted, or purified IgG) in a functional assaybased on antibody dependent phagocytosis of merozoite (APDm) by PMN. Theassay is described in Example 19.

DETAILED DESCRIPTION OF THE INVENTION

Two recently identified merozoite surface antigens, Plasmodiumfalciparum merozoite surface proteins 4 and 5 (PfMSP4 and PfMSP5), arepromising protein constituents of a potential multi-componentanti-malaria vaccine. The msp4 and msp5 genes both code for 272 residueproteins, each with a single C-terminal EGF-like domain and GPIattachment motif [10,11] and are located in tandem on chromosome 2, justupstream of msp2. Membrane association at the merozoite surface has beendemonstrated for both proteins, and human immune sera have been shown toreact with recombinant MSP4 expressed in Escherichia coli [12,13].

In 3 murine species of Plasmodium, P. yoelii, P. chabaudi, and P.berghei, there is only a single gene at the MSP4 and MSP5 locus(MSP4/5), which shows some degree of homology to each [14-16]. This geneis denoted MSP4/5 and has been used to investigate protective immunityin the P. yoelii lethal challenge model [17].

MSP4/5 has been shown to confer protection using a variety ofimmunization strategies, and efficacy is maximized when delivered inconjunction with MSP1p19 [17-20]. In addition, there appears to be nostrain specificity in immune responses induced by the murine MSP4/5protein [21]. In P. falciparum, msp4 and msp5 each have a single intronat homologous locations [22].

Plasmodium falciparum merozoite surface protein 4 (PfMSP4) proteinsequence includes a secretory signal sequence, a C-terminal EGF-likedomain, and GPI-attachment signal [10].

The Pfmsp4 gene sequence is 960 by in length, includes one intron of 144by and encodes 272 amino acids residues. The Pfmsp5 gene sequence is 955by in length, includes one intron of 136 by and encodes 272 amino acidsresidues. As for PfMSP4, the PfMSP5 protein sequence consists of asecretory signal sequence, a C-terminal EGF-like domain, and aGPI-attachment signal [11,22]. Downstream of this cluster of MSP genesis the highly conserved adenylosuccinate lysase (ASL) gene, which hasproved to be a useful handle to facilitate the identification of thislocus in other species (FIG. 1).

Much current data support the notion that PfMSP4 and PfMSP5 are goodvaccine candidates. Nevertheless, several published findings show thatrecombinant analogs of PfMSP4 produced in two different expressionsystems (E. coli and yeast) differ in antigenicity and induceconformationally-independent responses against the EGF-like domain ofthe protein, a phenomenon not seen with human immune sera [13]. Ifrecognition of conformational epitopes in this region of the protein isimportant for protection, as is the case with MSP1-19, it is imperativeto generate a product that faithfully reproduces all epitopes.

Accordingly, the invention provides constructs in which the nucleicacids encoding Plasmodium falciparum MSP4 and MSP5, and the resultingpolypeptides, have been modified to achieve optimal expression in insectcells. More particularly, this invention provides constructs encodingrecombinant MSP4 polypeptides, which are expressed as soluble, secretedpolypeptides in a baculovirus-insect cell expression system. Therecombinant polypeptides contain an EGF-like domain at the C-terminusthat appears to be properly folded. This is indicated by a markedreduction (50-60%) in polyclonal rabbit sera recognition of MSP4 whenthe protein is irreversibly reduced on ELISA plates (see FIG. 12)

One of the recombinant MSP4 polypeptides of the invention is a MSP4exo-antigen (minus C-terminal hydrophobic residues of the GPI attachmentsite, thus allowing protein secretion) with a deletion of 30 amino acidsfrom the polymorphic region near the N-terminus. This polypeptide of theinvention is referred to as MSP4p30.

Another one of the recombinant MSP4 polypeptides of the invention is aMSP4 exo-antigen (minus C-terminal hydrophobic residues of the GPIattachment site, thus allowing protein secretion) without a deletion of30 amino acids from a polymorphic region near the N-terminus. Thispolypeptide of the invention is referred to as MSP4p40 and is thefull-length gene product.

Another recombinant MSP4 polypeptide of the invention is a 20 kDapolypeptide corresponding approximately to the C-terminal half of MSP4,starting around the sequence KSPKE motif and including the EGF domain.Upstream supplementary amino acid residues could be included, inparticular residues of the MSP4p40 sequence localized upstream the KSPKEmotif. This recombinant polypeptide of the invention is referred to asMSP4p20.

In addition, this invention provides recombinant MSP5 polypeptidesincluding p35 and p45 forms that are produced simultaneously. Bothcontain a post-translational modification, likely to involve thecovalent attachment of a fatty acid residues (myristoylation) that canboost immunogenicity. These recombinant polypeptides of the inventionare referred to as MSP5p45 and MSP5p35.

Nevertheless, the recombinant MSP4 and MSP5 polypeptides of theinvention can be also expressed as C-terminal GPI anchored entitiesusing either their native GPI signal sequences or that from another GPIanchored protein sequence signaling for GPI modification. Such GPImodified entities would be expected to substantially enhanceimmunogenicity of the recombinant MSP4 and MSP5 polypeptides in theabsence of any adjuvants of immunity.

The recombinant polypeptides of the invention are described in greaterdetail with reference to their corresponding SEQ ID NOS. as follows:

Nucleic Acids

MSP4p20 SEQ ID NO: 1

MSP4p30 SEQ ID NO: 2

MSP4p40 SEQ ID NO: 3

MSP5 SEQ ID NO: 4

MSP5p10 SEQ ID NO: 5

MSP4p21 SEQ ID NO: 6

MSP4p21 ss1 SEQ ID NO: 7 and SEQ ID NO: 28

MSP4p21 ss2 SEQ ID NO: 8 and SEQ ID NO: 29

Polypeptides

-   -   MSP4p20 (breakdown product) SEQ ID NO: 9    -   MSP4p30 (ORF present in the construct=polypeptide encoded by the        construct) SEQ ID NO: 10    -   MSP4p30 (final product of expression=polypeptide produced by        insect cells) SEQ ID NO: 11    -   MSP4p40 (ORF present in the construct) SEQ ID NO: 12    -   MSP4p40 (final product of expression) SEQ ID NO: 13    -   MSP5 (ORF present in construct) SEQ ID NO: 14    -   MSP5p10 SEQ ID NO: 15    -   PvMSP4/His SEQ ID NO: 16    -   MSP4p21 (ORF present in the construct) SEQ ID NO: 17    -   MSP4p21 (final product of expression) SEQ ID NO: 18    -   MSP4p21 ss1 (ORF present in the construct) SEQ ID NO: 19    -   MSP4p21 ss1 (final product of expression) SEQ ID NO: 20    -   MSP4p21 ss2 (ORF present in the construct) SEQ ID NO: 21    -   MSP4p21 ss2 (final product of expression) SEQ ID NO: 22    -   PvMSP4p20 (sequence of proposed vaccine construct based on        Plasmodium vivax sequence of MSP4 as given in “alignment of        amino acid sequences of PfMSP4 and PvMSP4) SEQ ID NO: 30

These polypeptides are individually and collectively referred to hereinas “the recombinant MSP4 and MSP5 polypeptides” of the invention.Similarly, the nucleic acids encoding these polypeptides are referred toas “the recombinant MSP4 and MSP5 nucleic acids” of the invention.

The implications for this invention are widespread. This discovery ofthe recombinant MSP4 and MSP5 polypeptides enables construction ofexpression vectors comprising nucleic acid sequences encodingrecombinant MSP4 and MSP5 polypeptides of the invention; host cellstransfected or transformed with the expression vectors; biologicallyactive recombinant MSP4 and MSP5 polypeptides and recombinant MSP4 andMSP5 polypeptides as isolated or purified proteins; antibodiesimmunoreactive with recombinant MSP4 and MSP5 polypeptides, diagnosticuse of the recombinant MSP4 and MSP5 polypeptides and antibodiesdirected against the recombinant MSP4 and MSP5 polypeptides in detectionof Plasmodium parasite and malaria infection and vaccine use of therecombinant MSP4 and MSP5 polypeptides to protect against Plasmodiuminfection.

As used herein, the term “recombinant MSP4 and MSP5 polypeptides” alsorefers to a genus of polypeptides that further encompasses proteinshaving the amino acid sequence of SEQ ID NOS: 9-22, as well as thoseproteins and polypeptides having a high degree of similarity (at least90% homology) with such amino acid sequences and which proteins andpolypeptides are immunoreactive. In addition, recombinant MSP4 and MSP5polypeptides refers to the gene products of the nucleotides of SEQ IDNOS: 1-8.

The term “purified” as used herein, means that the recombinant MSP4 andMSP5 polypeptides are essentially free of association with otherproteins or polypeptides, for example, as a purification product ofrecombinant host cell culture or as a purified product from anon-recombinant source. The term “substantially purified” as usedherein, refers to a mixture that contains recombinant MSP4 and MSP5polypeptides and is essentially free of association with other proteinsor polypeptides, but for the presence of known proteins that can beremoved using a specific antibody, and which substantially purifiedrecombinant MSP4 and MSP5 polypeptides can be used as antigens.

A recombinant MSP4 and MSP5 polypeptide “variant” as referred to hereinmeans a polypeptide substantially homologous to recombinant MSP4 andMSP5 polypeptides, but which has an amino acid sequence different fromthat of recombinant MSP4 and MSP5 polypeptides because of one or moredeletions, insertions, or substitutions. The variant amino acid sequencepreferably is at least 80% identical to a recombinant MSP4 and MSP5polypeptide amino acid sequence, most preferably at least 90% identical.The percent identity can be determined, for example by comparingsequence information using the GAP computer program, version 6.0described by Devereux et al. (Nucl. Acids Res. 12:387, 1984) andavailable from the University of Wisconsin Genetics Computer Group(UWGCG). The GAP program utilizes the alignment method of Needleman andWunsch (J. Mol. Biol. 48:443, 1970), as revised by Smith and Waterman(Adv. Appl. Math 2:482, 1981). The preferred default parameters for theGAP program include: (1) a unary comparison matrix (containing a valueof 1 for identities and 0 for non-identities) for nucleotides, and theweighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res.14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas ofProtein Sequence and Structure, National Biomedical Research Foundation,pp. 353-358, 1979; (2) a penalty of 3.0 for each gap and an additional0.10 penalty for each symbol in each gap; and (3) no penalty for endgaps.

Variants can comprise conservatively substituted sequences, meaning thata given amino acid residue is replaced by a residue having similarphysiochemical characteristics. Examples of conservative substitutionsinclude substitution of one aliphatic residue for another, such as Ile,Val, Leu, or Ala for one another, or substitutions of one polar residuefor another, such as between Lys and Arg; Glu and Asp; or Gln and Asn.Other such conservative substitutions, for example, substitutions ofentire regions having similar hydrophobicity characteristics, are wellknown. Examples of variants of the MSP4 and MSP5 polypeptides of theinvention are proteins that result from alternate mRNA splicing eventsor from proteolytic cleavage of the recombinant MSP4 and MSP5polypeptides. Variations attributable to proteolysis include, forexample, differences in the termini upon expression in different typesof host cells, due to proteolytic removal of one or more terminal aminoacids from the recombinant MSP4 and MSP5 polypeptides. Variationsattributable to frame shifting include, for example, differences in thetermini upon expression in different types of host cells.

As stated above, the invention provides isolated and purified, orhomogeneous, recombinant MSP4 and MSP5 polypeptides. Variants andderivatives of recombinant MSP4 and MSP5 polypeptides that can be usedas antigens can be obtained by mutations of nucleotide sequences codingfor recombinant MSP4 and MSP5 polypeptides. Alterations of the aminoacid sequence can be accomplished by any of a number of conventionalmethods. Mutations can be introduced at particular loci by synthesizingoligonucleotides containing a mutant sequence, flanked by restrictionsites enabling ligation to fragments of the native sequence. Followingligation, the resulting reconstructed sequence encodes an analoguehaving the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed, site-specific mutagenesisprocedures can be employed to provide an altered gene whereinpredetermined codons can be altered by substitution, deletion, orinsertion. Exemplary methods of making the alterations set forth aboveare disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al.(Genetic Engineering: Principles and Methods, Plenum Press, 1981);Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985); Kunkel et al. (Methodsin Enzymol. 154:367, 1987); and U.S. Pat. Nos. 4,518,584 and 4,737,462,all of which are incorporated by reference.

Within an aspect of the invention, recombinant MSP4 and MSP5polypeptides can be utilized to prepare antibodies that specificallybind to recombinant MSP4 and MSP5 polypeptides. The term “antibodies” ismeant to include polyclonal antibodies, monoclonal antibodies, fragmentsthereof, such as F(ab′)2 and Fab fragments, as well as any recombinantlyproduced binding partners. Antibodies are defined to be specificallybinding if they bind recombinant MSP4 and MSP5 polypeptides with a Ka ofgreater than or equal to about 107 M−1. Affinities of binding partnersor antibodies can be readily determined using conventional techniques,for example, those described by Scatchard et al., Ann. N.Y. Acad. Sci.,51:660 (1949). Polyclonal antibodies can be readily generated from avariety of sources, for example, horses, cows, goats, sheep, dogs,chickens, rabbits, mice, or rats, using procedures that are well knownin the art.

The invention further encompasses isolated fragments andoligonucleotides derived from the nucleotide sequences of SEQ ID NOS: 1,2, 3, 4, 5, 6, 7, and 8. The invention also encompasses polypeptidesencoded by these fragments and oligonucleotides.

Nucleic acid sequences within the scope of the invention includeisolated DNA and RNA sequences that hybridize to the native recombinantMSP4 and MSP5 nucleic acids disclosed herein under conditions ofmoderate or severe stringency, and which encode recombinant MSP4 andMSP5 polypeptides. As used herein, conditions of moderate stringency, asknown to those having ordinary skill in the art, and as defined bySambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1,pp. 1.101-104, Cold Spring Harbor Laboratory Press, (1989), include useof a prewashing solution for the nitrocellulose filters 5×SSC, 0.5% SDS,1.0 mM EDTA (pH 8.0), hybridization conditions of 50% formamide, 6×SSCat 42° C. (or other similar hybridization solution, such as Stark'ssolution, in 50% formamide at 42° C.), and washing conditions of about60° C., 0.5×SSC, 0.1% SDS. Conditions of high stringency are defined ashybridization conditions as above, and with washing at 68° C., 0.2×SSC,0.1% SDS. The skilled artisan will recognize that the temperature andwash solution salt concentration can be adjusted as necessary accordingto factors such as the length of the probe.

Due to the known degeneracy of the genetic code, wherein more than onecodon can encode the same amino acid, a DNA sequence can vary from thatshown in SEQ ID NOS: 1-8, and still encode a recombinant MSP4 and MSP5polypeptide having the amino acid sequence of SEQ ID NOS: 9-22. Suchvariant DNA sequences can result from silent mutations (e.g., occurringduring PCR amplification), or can be the product of deliberatemutagenesis of a native sequence.

The invention thus provides equivalent isolated DNA sequences, encodingrecombinant MSP4 and MSP5 polypeptides, selected from: (a); (a) DNAcomprising the nucleotide sequence of SEQ ID NOS: 1-8 (b) DNA capable ofhybridization to a DNA of (a) under conditions of moderate stringencyand which encode recombinant MSP4 and MSP5 polypeptides; and (c) DNAwhich is degenerate as a result of the genetic code to a DNA defined in(a), or (b) and which encodes recombinant MSP4 and MSP5 polypeptides.The polypeptides encoded by such DNA equivalent sequences areencompassed by the invention.

DNA that is equivalent to the DNA sequence of SEQ ID NOS: 1-8 willhybridize under moderately stringent conditions to the DNA sequence thatencode polypeptides comprising amino acid sequences of SEQ ID NOS: 9-22.Examples of recombinant MSP4 and MSP5 polypeptides encoded by such DNA,include, but are not limited to, recombinant MSP4 and MSP5 polypeptidefragments and recombinant MSP4 and MSP5 polypeptides comprisinginactivated N-glycosylation site(s), inactivated protease processingsite(s), or conservative amino acid substitution(s), as described above.The polypeptides encoded by DNA derived from other species ofPlasmodium, wherein the DNA will hybridize to the complement of the DNAof SEQ ID NOS: 1-8 are also encompassed.

Recombinant expression vectors containing a nucleic acid sequenceencoding recombinant MSP4 and MSP5 polypeptides can be prepared usingwell known methods. The expression vectors include a recombinant MSP4and MSP5 DNA sequence operably linked to suitable transcriptional ortranslational regulatory nucleotide sequences, such as those derivedfrom a mammalian, microbial, viral, or insect gene. Examples ofregulatory sequences include transcriptional promoters, operators, orenhancers, an mRNA ribosomal binding site, and appropriate sequenceswhich control transcription and translation initiation and termination.Nucleotide sequences are “operably linked” when the regulatory sequencefunctionally relates to the recombinant MSP4 and MSP5 DNA sequence.Thus, a promoter nucleotide sequence is operably linked to a recombinantMSP4 and MSP5 DNA sequence if the promoter nucleotide sequence controlsthe transcription of the recombinant MSP4 and MSP5 DNA sequence. Theability to replicate in the desired host cells, usually conferred by anorigin of replication, and a selection gene by which transformants areidentified can additionally be incorporated into the expression vector.

In addition, sequences encoding appropriate signal peptides that are notnaturally associated with recombinant MSP4 and MSP5 polypeptides can beincorporated into expression vectors. For example, a DNA sequence for asignal peptide (secretory leader) can be fused in-frame to therecombinant MSP4 and MSP5 nucleotide sequences so that the recombinantMSP4 and MSP5 polypeptides are initially translated as a fusion proteincomprising the signal peptide. A signal peptide that is functional inthe intended host cells enhances extra-cellular secretion of therecombinant MSP4 and MSP5 polypeptides. The signal peptide can becleaved from the recombinant MSP4 and MSP5 polypeptides upon secretionof recombinant MSP4 and MSP5 polypeptides from the cell.

Expression vectors for use in prokaryotic host cells generally compriseone or more phenotypic selectable marker genes. A phenotypic selectablemarker gene is, for example, a gene encoding a protein that confersantibiotic resistance or that supplies an autotrophic requirement.Examples of useful expression vectors for prokaryotic host cells includethose derived from commercially available plasmids. Commerciallyavailable vectors include those that are specifically designed for theexpression of proteins. These include pMAL-p2 and pMAL-c2 vectors, whichare used for the expression of proteins fused to maltose binding protein(New England Biolabs, Beverly, Mass., USA).

Promoter sequences commonly used for recombinant prokaryotic host cellexpression vectors include β-lactamase (penicillinase), lactose promotersystem (Chang et al., Nature 275:615, 1978; and Goeddel et al., Nature281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl.Acids Res. 8:4057, 1980; and EP-A-36776), and tac promoter (Maniatis,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory,p. 412, 1982).

Suitable host cells for expression of recombinant MSP4 and MSP5polypeptides include prokaryotes, yeast or higher eukaryotic cells.Insect cells are preferred. Appropriate cloning and expression vectorsfor use with bacterial, fungal, yeast, and mammalian cellular hosts aredescribed, for example, in Pouwels et al. Cloning Vectors: A LaboratoryManual, Elsevier, New York, (1985). Cell-free translation systems couldalso be employed to produce recombinant MSP4 and MSP5 polypeptides usingRNAs derived from DNA constructs disclosed herein.

It will be understood that the present invention is intended toencompass the previously described proteins or polypeptides in isolatedor purified form, whether obtained using the techniques described hereinor other methods. In a preferred embodiment of this invention, therecombinant MSP4 and MSP5 polypeptides are substantially free of humantissue and human tissue components, nucleic acids, extraneous proteinsand lipids, and adventitious micro-organisms, such as bacteria andviruses. It will also be understood that the invention encompassesequivalent proteins having substantially the same biological andimmunogenic properties.

Depending on the use to be made of the recombinant MSP4 and MSP5polypeptides of the invention, it may be desirable to label them.Examples of suitable labels are radioactive labels, enzymatic labels,fluorescent labels, chemiluminescent labels, and chromophores. Themethods for labelling proteins of the invention do not differ in essencefrom those widely used for labelling immunoglobulin. The need to labelmay be avoided by using labelled antibody to the antigen of theinvention or anti-immunoglobulin to the antibodies to the antigen as anindirect marker.

Once the recombinant MSP4 and MSP5 polypeptides of the invention havebeen obtained, they have been used to produce polyclonal and monoclonalantibodies reactive therewith. Thus, a protein or polypeptide of theinvention can be used to immunize an animal host by techniques known inthe art. Such techniques usually involve inoculation, but they mayinvolve other modes of administration. A sufficient amount of thepolypeptide is administered to create an immunogenic response in theanimal host. Any host that produces antibodies to the antigen of theinvention can be used. Once the animal has been immunized and sufficienttime has passed for it to begin producing antibodies to the antigen,polyclonal antibodies can be recovered. The general method comprisesremoving blood from the animal and separating the serum from the blood.The serum, which contains antibodies to the antigen, can be used as anantiserum to the antigen. Alternatively, the antibodies can be recoveredfrom the serum. Affinity purification is a preferred technique forrecovering purified polyclonal antibodies to the antigen from the serum.

Monoclonal antibodies to the antigens of the invention can also beprepared. One method for producing monoclonal antibodies reactive withthe antigens comprises the steps of immunizing a host with the antigen;recovering antibody producing cells from the spleen of the host; fusingthe antibody producing cells with myeloma cells deficient in the enzymehypoxanthine-guanine phosphoribosyl transferase to form hybridomas;selecting at least one of the hybridomas by growth in a mediumcomprising hypoxanthine, aminopterin, and thymidine; identifying atleast one of the hybridomas that produces an antibody to the antigen;culturing the identified hybridoma to produce antibody in a recoverablequantity; and recovering the antibodies produced by the culturedhybridoma.

These polyclonal or monoclonal antibodies can be used in a variety ofapplications. Among these is the neutralization of correspondingproteins. They can also be used to detect Plasmodium parasite antigensin biological preparations or in purifying corresponding proteins,glycoproteins, or mixtures thereof, for example, when used in anaffinity chromatographic column.

The recombinant MSP4 and MSP5 polypeptides can be used as antigens todetect the presence of antibodies specific for malaria parasite inbiological samples and to evaluate the levels of such antibodies inthose biological samples, which constitute a signal for current orprevious infection. Such biological samples of course include humantissue and human cells, as well as biological fluids, such as human bodyfluids, including human sera. When used as a reagent in an immunoassayfor determining the presence or concentration of the antibodies tomalaria, the antigens of the present invention provide an assay that isconvenient, rapid, sensitive, and specific.

More particularly, the antigens of the invention can be employed for thedetection of malaria by means of immunoassays that are well known foruse in detecting or quantifying humoral components in fluids. Thus,antigen-antibody interactions can be directly observed or determined bysecondary reactions, such as precipitation or agglutination. Inaddition, immunoelectrophoresis techniques can also be employed. Forexample, the classic combination of electrophoresis in agar followed byreaction with anti-serum can be utilized, as well as two-dimensionalelectrophoresis, rocket electrophoresis, and immunolabelling ofpolyacrylamide gel patterns (Western Blot or immunoblotting). Otherimmunoassays in which the antigens of the present invention can beemployed include, but are not limited to, radioimmunoassay, competitiveimmunoprecipitation assay, enzyme immunoassay, and immunofluorescenceassay. It will be understood that turbidimetric, colorimetric, andnephelometric techniques can also be employed. An immunoassay based onWestern Blot technique is preferred.

Immunoassays can be carried out by immobilizing one of theimmunoreagents, either an antigen of the invention or an antibody of theinvention to the antigen, on a carrier surface while retainingimmunoreactivity of the reagent. The reciprocal immunoreagent can beunlabeled or labelled in such a manner that immunoreactivity is alsoretained. These techniques are especially suitable for use in enzymeimmunoassays, such as enzyme linked immunosorbent assay (ELISA) andcompetitive inhibition enzyme immunoassay (CIEIA).

When either the antigen of the invention or antibody to the antigen isattached to a solid support, the support is usually a glass or plasticmaterial. Plastic materials moulded in the form of plates, tubes, beads,or disks are preferred. Examples of suitable plastic materials arepolystyrene and polyvinyl chloride. If the immunoreagent does notreadily bind to the solid support, a carrier material can be interposedbetween the reagent and the support. Examples of suitable carriermaterials are proteins, such as bovine serum albumin, or chemicalreagents, such as gluteraldehyde or urea. Coating of the solid phase canbe carried out using conventional techniques.

The invention provides immunogenic recombinant MSP4 and MSP5polypeptides, and more particularly, protective polypeptides for use inthe preparation of vaccine compositions against malaria. Thesepolypeptides can thus be employed as vaccines by administering thepolypeptides to a mammal susceptible to malaria infection. Conventionalmodes of administration can be employed. For example, administration canbe carried out by oral, sublingual, respiratory, or parenteral routes.Intradermal, subcutaneous, intramuscular, and intravenous routes ofadministration are preferred when the vaccine is administeredparenterally.

The major purpose of the immune response in a malaria-infected mammal isto inactivate the malaria parasites and to facilitate malaria parasitekilling and clearance of parasite infected red blood cells. The B-cellarm of the immune response has the major responsibility for inactivatingblood-stage malaria parasites. The principal manner in which this isachieved is by neutralization of infectivity (inhibition of erythrocyteinvasion) and antibody dependent cellular cytotoxicity (ADCC). Thetarget antigen must be conserved to be effective against re-infectionwith other parasite strains, and capable of inducing T helper cellactivity (CD4+) to generate a long-lived memory response. T cellmediated mechanism for destruction of parasite infected cells isprovided by cytotoxic (CD8+) T lymphocytes (CTL) that could recognizerecombinant MSP4 and MSP5 antigens expressed in combination with Class Ihistocompatibility antigens at the surface of hepatic cells in thepreerythrocytic phase of infection.

Following is a vaccine, which includes (A) the natural signal sequence(B) a C-terminal His tag and (C) the acid repeat region that resemblesthat of the P. falciparum antigen most strongly correlated withprotective antibody responses in the field (MSP4p20).

[SEQ ID NO: 30] MKVAYFLSVLDLLIIFSLYFDGRRSAFAGIAACIRHGRILGEGGE/QNSTPGSGGQTGDHSAEAENGDYNEQGDDHGDDHGDDHGDDHGDEQDGEDYDDAEDDDLYELSEVDENANLCLDNNGGCGDDKICENLGKGIVKCLCKPGYKLV GTECVEHHHHHH

The ability of the recombinant MSP4 and MSP5 polypeptides and vaccinesof the invention to induce protective levels of neutralizing antibody(i.e., antibodies elicited during a humoral response to the antigen,which directly blocks the ability of the pathogen to infect red bloodcells) in a host can be enhanced by emulsification with an adjuvant(immunostimulator), incorporating in a liposome, coupling to a suitablecarrier, or by combinations of these techniques. For example, therecombinant MSP4 and MSP5 polypeptides of the invention can beadministered with a conventional adjuvant, such as aluminium phosphateand aluminium hydroxide gel, in an amount sufficient to potentiatehumoral or cell-mediated immune responses in the host.

The immunization schedule will depend upon several factors, such as thesusceptibility of the host to infection and the age of the host. Asingle dose of the vaccine of the invention can be administered to thehost or a primary course of immunization can be followed in whichseveral doses at intervals of time are administered. Subsequent dosesused as boosters can be administered as needed following the primarycourse.

The recombinant MSP4 and MSP5 proteins, polypeptides, and vaccines ofthe invention can be administered to the host in an amount sufficient toinduce immune responses that prevent or inhibit parasite infection andreplication in vivo so as to reduce the parasite burden in the host anddiminish clinical symptoms. An immunogenic response can be obtained byadministering the polypeptides of the invention to the host in amountsranging from 10 to 500 micrograms per dose, preferably about 50 to 100micrograms per dose. The proteins and vaccines of the invention can beadministered together with a physiologically acceptable carrier. Forexample, a diluent, such as water or a saline solution, can be employed.

Another aspect of the invention provides a method of DNA vaccination.The method also includes administering any combination of the nucleicacids encoding recombinant MSP4 and MSP5 polypeptides, the proteins andpolypeptides per se, with or without carrier molecules, to anindividual. In embodiments, the individual is an animal, and ispreferably a mammal. More preferably, the mammal is selected from thegroup consisting of a human, a dog, a cat, a bovine, a pig, and a horse.In an especially preferred embodiment, the mammal is a human.

Those of skill in the art are cognizant of the concept, application, andeffectiveness of nucleic acid vaccines (e.g., DNA vaccines) and nucleicacid vaccine technology as well as protein and polypeptide basedtechnologies. The nucleic acid based technology allows theadministration of nucleic acids encoding recombinant MSP4 and MSP5polypeptides, naked or encapsulated, directly to tissues and cellswithout the need for production of encoded proteins prior toadministration. The technology is based on the ability of these nucleicacids to be taken up by cells of the recipient organism and expressed toproduce an immunogenic determinant to which the recipient's immunesystem responds. Typically, the expressed antigens are displayed on thesurface of cells that have taken up and expressed the nucleic acids, butexpression and export of the encoded antigens into the circulatorysystem of the recipient individual is also within the scope of thepresent invention. Such nucleic acid vaccine technology includes, but isnot limited to, delivery of naked DNA and RNA and delivery of expressionvectors encoding recombinant MSP4 and MSP5 polypeptides. Although thetechnology is termed “vaccine”, it is equally applicable to immunogeniccompositions that do not result in a protective response. Suchnon-protection inducing compositions and methods are encompassed withinthe present invention.

Although it is within the present invention to deliver nucleic acidsencoding recombinant MSP4 and MSP5 polypeptides and carrier molecules asnaked nucleic acid, the present invention also encompasses delivery ofnucleic acids as part of larger or more complex compositions. Includedamong these delivery systems are viruses, virus-like particles, orbacteria containing the nucleic acid encoding recombinant MSP4 and MSP5polypeptides. Also, complexes of the invention's nucleic acids andcarrier molecules with cell permeabilizing compounds, such as liposomes,are included within the scope of the invention. Other compounds, such asmolecular vectors (EP 696,191, Samain et al.) and delivery systems fornucleic acid vaccines are known to the skilled artisan and exemplifiedin, for example, WO 93 06223 and WO 90 11092, U.S. Pat. No. 5,580,859,and U.S. Pat. No. 5,589,466 (Vical's patents), which are incorporated byreference herein, and can be made and used without undue or excessiveexperimentation.

This invention will be described in greater detail in the followingspecific embodiments.

It has been known for a long time that antigens generated using thebaculovirus expression system faithfully contain complex structuresinvolving the formation of cysteine bonds and are suitable forcrystallization studies. These antigens are commonly held as “the goldstandard” against which antigens produced in other systems are checked[24,25]. As both PfMSP4 and PfMSP5 contain EGF-like domains that areformed by disulphide bonds, they may benefit from being generated in thebaculovirus-system. However, as with all commonly used expressionsystems, protein yield is detrimentally affected by the unusual codonusage of P. falciparum[26,27]. In addition, these highly A+T richsequences are frequently mutated in E. coli [28] and rarely containunique restriction enzyme sites. For these reasons, synthetic genes weredesigned and constructed using the method described by Withers-Martinez(1999) [29].

Designing a synthetic gene

Based on the sequence data available from GenBank at the time, and withfuture applications in mind, including the human challenge model, thecommon amino acid sequences, PfMSP4 NF54 sequence (Ac No. AF295318) andPfMSP5 3D7 sequence (Ac No. AF106476), were selected for modification.In parallel, to enrich sequence data sets and perform inter andintra-population analysis and inter-species analysis, a polymorphismstudy was conducted using samples taken from locations of varyingendemicity as follows.

A Summary of msp4 and msp5 Gene Polymorphism

Antigen polymorphism is an important consideration when developing avaccine for P. falciparum. The most promising blood stage vaccinecandidates examined so far are merozoite surface protein 1, (MSP1) andan apical membrane antigen (AMA1 [1-3]. However, these and other surfaceantigen genes display a disproportionately high frequency ofnon-synonymous single nucleotide polymorphisms (nsSNPs) when compared togenes coding for antigens that are not accessible to immuneeffector-mechanisms [4-6]. As a compounding factor, these nsSNPsfrequently lead to radical amino acid substitutions that arepredominantly clustered within the regions of the peptide mostaccessible to the host immune system [7]. The resulting amino acidsubstitutions are believed to function in immune evasion by alteringimportant B and T cell epitopes [34,38]. Thus, vaccination with integralrecombinant versions of such antigens is likely to result in strainspecific protection [4,8]. It is widely believed that a globallyeffective vaccine will include the conserved portions of several surfaceproteins derived from multi-stage targets [30].

To date, only a limited amount of polymorphism data is available forPfMSP4 and PfMSP5 [11, 31, 32]. To fully explore polymorphism of bothPfMSP4 and PfMSP5 from highly endemic locations a sequence analysisstudy was conducted, the results of which are presented in Poison et al.2005 [33]. In summary, the Pfmsp5 gene sequence was found to be highlyconserved and potentially under purifying selection. The Pfmsp4 genesequence was found to be relatively conserved for a P. falciparumsurface antigen [5] and to contain an N-terminal cluster of polymorphicsites (residues 45-81), which includes two sites that are potentiallyunder balancing selection (N52 and G74). This would explain the observedclustering of apparently neutral (or hitchhiking) polymorphisms withinthe flanking sequences and could be linked to either B or T-cell epitopevariation. Balancing selection classically arises from the existence oftwo allelic gene sequences that harbour a “difference” which has animpact on immune recognition of the molecule. When allele A is mostcommon in the population, it is an advantage to be allele B, as thisallele will not be recognised by the immune system as well as thedominant allele. Thus, allele B becomes more common until it is the mostfrequent type, the immune system will become competent for the B allele,at which point it is an advantage to be allele A. First, the presence ofbalancing selection suggests that the MSP4 protein is the target of aneffective immune mechanism. Second, this suggests that to protect peoplein the field you would need to vaccinate with both alleles, or excludethis region of the protein, forcing the immune system to act againstconserved regions. With regard to the recent identification of twoPfMSP4 derived peptides capable of specifically binding hepatocytes[34], the first (which represents residues 76-92 of MSP4p40) harboursone semi-conservative polymorphism (A81), and the second (whichrepresents residues 113-135 of MSP4p40) contains one deletion (115-119)and/or one semi-conservative polymorphism (G119). In the existing PfMSP4data sets, differences within these sequences are present at relativelylow frequencies, supporting the idea that these are functionallyimportant sites (Note; these sequences are also represented by SALSA,FIG. 2). Finally, there is one more site potentially under balancingselection, V190, which lies 17 residues upstream of the first cysteineof the EGF-like domain, once again this could be involved in either B orT-cell epitope modifications.

Construction of a Synthetic Gene; PfMSP4

First, to facilitate protein secretion, all sequence starting threeresidues downstream of the EGF domain was removed. This included the GPIattachment signal, as it is known that the baculovirus system can usesuch sequences to incorporate insect cell GPI-moieties and results incell surface localisation of the protein (Bonnet et al. 2006). Inaddition, the natural signal MSP4 sequence was retained since thebaculovirus expression system is known to correctly cleave the nativeMSP1 signal sequence in recombinant analogs, although the native cleavedN-terminus of MSP4 has not been defined. To prevent N-glycosylation,which is not known to occur in Plasmodium but does occur in baculovirusat two potential sites in the PfMSP4 sequence, the serine residues S₆₅and S₇₃ substituted for alanine. Both residues have small side chains(Ser=HO—CH₂—, Ala=CH₃—) and although these sites have not been reportedto be naturally polymorphic, these changes are believed to have aminimal effect on the local or macro structure of the protein. Once theremaining features had been added, including a C-terminal hexa-his-tagand stop codon, the sequence was back translated using the CODOP programset to Trichoplusia ni (High Five) cell codon usage (Table 1).

MSP4 codon usage of NF54 and synthetic gene Codon aa p.f H5 GCA Ala 2 4GCC 0 1 GCG 1 0 GCT 3 3 total 6 8 AGA Arg 4 0 AGG 0 1 CGA 0 0 CGC 0 1CGG 0 0 CGT 0 2 total 4 4 AAC Asn 2 17 AAT 15 0 total 17 17 GAC Asp 7 22GAT 18 3 total 25 25 TGC Cyc 0 4 TGT 7 3 total 7 7 CAA Gln 5 3 CAG 0 2total 5 5 GAA Glu 36 25 GAG 4 15 total 40 40 GGA Gly 11 13 GGC 1 2 GGG 30 GGT 4 4 total 19 19 CAC His 1 12 CAT 6 1 total 7 13 ATA Ile 5 1 ATC 25 ATT 3 4 total 10 10 CTA Leu 2 1 CTC 0 2 CTG 0 0 CTT 0 3 TTA 6 0 TTG 24 total 10 10 ATG Met 4 4 total 4 4 AAA Lys 24 5 AAG 7 26 total 31 31TTC Phe 0 4 TTT 4 0 total 4 4 CCA Pro 4 2 CCC 1 1 CCG 0 0 CCT 2 4 total7 7 AGC Ser 1 3 AGT 6 4 TCA 4 1 TCC 3 1 TCG 0 1 TCT 5 7 total 19 17 TAAstop 0 1 TAG 0 0 TGA 0 0 total 0 1 ACA Thr 1 3 ACC 1 3 ACG 0 0 ACT 5 1total 7 7 TGG Trp 1 1 total 1 1 TAC Tyr 0 6 TAT 6 0 total 6 6 GTA Val 53 GTC 0 5 GTG 1 3 GTT 10 5 total 16 16 p.f. H5 Codons 245 252 % GC 30.647.5

CODOP is a Unix perl script which implements codon optimization asproposed by Hale and Thompson [35] and is described in detail elsewhere[29]. The re-codoned nucleotide sequence was subsequently optimised bymanual intervention to give rise to 38×40mers with a Tm of 60-65° C. andto contain several unique restriction sites to facilitate sub-cloning(FIG. 3).

The overall GC content of the gene was increased by 15%, vastlyincreasing the ease and efficiency of sub-cloning and reducing thefrequency of replication errors made by E. coli during constructmanipulation. The 38 overlapping oligonucleotides, each 40 bases inlength, were obtained from Eurogentec (with only standard purification).Gene assembly and amplification were achieved as previously described[29].

In brief, gene oligonucleotides were mixed in equi-molar quantities (25μM each), and diluted 10-fold in to a 50 μL PCR reaction containing 1 μLof pfu DNA polymerase (Stratagene), 5 μL of 10× product buffer, 200 μMdNTPs and 2 μL of 25 mM MgSO₄. The PCR program consisted of onedenaturation step of 94° C. for 1 min, followed by 25 cycles of 94° C.for 30 s, 52° C. for 30 s and 72° C. for 2 min. To amplify thefull-length gene product, 5 μL of the gene assembly reaction werediluted 10-fold into a 50 μL PCR reaction containing 1 μL of pfu DNApolymerase (Stratagene), 5 μL of 10× product buffer, 200 μM dNTPs, 2 μLof 25 mM MgSO₄ and the outer gene assembly oligonucleotide numbers 1 and20 at 500 nM each. The PCR program consisted of one cycle of 94° C. for1 min, 25 cycles of 94° C. for 45 s, 68° C. for 45 s and 72° C. for 2min and a final elongation step of 72° C. for 10 min. The dominant andcorrectly sized fragment, shown in FIG. 4, was gel extracted, clonedinto pMOSBlue for sequencing and finally transferred into the vectorpVL1393 for integration into the Baculoviral genome (Baculogold,PharMingen). This expression construct is called MSP4p40/His.

Modified PfMSP4 Constructs

Two additional MSP4 constructs were also assembled, named MSP4-EGF/Hisand MSP4p30/His (FIG. 5). The construct MSP4-EFG/His was designed toexpress the MSP4 EGF-like domain only, mainly for the purpose ofcrystallisation studies. A PCR fragment containing the predicted signalsequence as described by PlasmoDB (residues 1-20) and 2 downstreamresidues was generated by high fidelity PCR. Reactions contained geneassembly oligonucleotide 1 and reverse primer MSP4modI(5′-TAT-AGC-AGA-TCT-TTG-TCG-AAG-TTG-ATG-GTG-CA-3′) [SEQ ID NO: 23] whichcontains a Bgl II restriction site. The synthetic gene clone pMosMSP4was used as a template. The resultant 86 by PCR product was cleaved withrestriction enzymes Bam HI and Bgl II and gel extracted. The product wasthen ligated (T4 DNA ligase; NEB) into previously prepared pMosMSP4vector, also digested with Bam HI and Bgl II to remove all sequenceupstream of the EGF-like domain, leaving residues D205 to H252.

The MSP4p30/His construct was designed to remove 30 residues from theC-terminal of MSP4 (residue 45 to 74) where the majority of the reportedpolymorphisms reside (Highlighted in FIG. 5). A PCR fragment encodingresidues 1 to 44 was generated using gene assembly oligonucleotide 1,reverse primer MSP4modII (5′-ATA TGG CTG CAG CCA AGA TCC TCA TGT TAA GCAT-3′) [SEQ ID NO: 24] and pMosMSP4 vector as a template. The fragmentwas 154 bp in size and had restriction sites Bam HI and Pst I at theextreme 3′ and 5′ ends respectively. A fragment of DNA encoding allsequence down stream of residue A75 was cut from vector pMosMSP4 usingrestriction enzymes Pst I and Spe I (which lies downstream of the MSP4ORF, within the pMOSBlue vector sequence). The two DNA fragments werecombined in equi-molar quantities in a T4 DNA ligase (NEB) reaction andincubated at 4° C. over 3 days. Resolution of 2 μL of the ligasereaction in a 1% agarose gel stained with ethidium bromide revealed thepresence of several products, including the required product, 724 bp inlength. This product was amplified by high fidelity PCR using geneassembly oligonucleotide 1 and 20 and 1 μL of the ligation reaction as atemplate, gel extracted and cloned back into pMOSBlue. As with thesynthetic gene, the MSP4-EGF/His and MSP4p30/His gene sequences wereconfirmed before being cloned into the expression vector pVL1393.

A further expression construct was designed and constructed from thesynthetic MSP4 gene described above. This expression cassette wasdesigned to allow expression of the non-polymorphic, protease resistantand structurally intact C-terminal region of the protein (called p20 anddescribed in later sections). This construct includes all nucleotidesequence downstream of the xba I cloning site of MSP4p40/His, and thusencodes all residues downstream of Leu₁₃₀ (non-included). To facilitateprotein secretion, a PCR fragment encoding the MSP4 signal sequence plus9 downstream residues (Met₁-Pro₄₉) was generated using gene assemblyoligo 1 and the reverse primer MSP4p21 rev (ATT AAT CTA GAG GCT TTT CTTCAC CCA AGA TCC TCA TG) SEQ ID NO: 25 and ligated into Bam HI/Xba Idouble digested pMosMSP4p40/His. This construct was named MSP4p21/Hisand the sequence was confirmed before being ligated into pVL1319 forintegration into the Baculovirus genome. Two supplementary similarexpression constructs were further designed and constructed from thesynthetic MSP4 gene described above. These constructs were named MSP4p21ss1 and MSP4p21 ss2 and both encode all residues downstream of Leu130.To facilitate protein secretion the same sequence coding for MSP4 signalsequence (Met₁-Pro₄₉) as in MSP4p21/His was added. Furthermore somecodons of MSP4p40/His construct were added, encoding the sequence(Asn₅₀-Ser57 and Leu₁₃₀) in MSP4p21 ss1 construct and encoding the aminoacid residue Leu₁₃₀ in MSP4p21 ss2.

Construction of the PfMSP5 Synthetic Gene

The same procedure as that described for Pfmsp4 was employed to designthe Pfmsp5 synthetic gene. Starting with the GenBank protein sequence ofthe 3D7 strain, all sequence starting three residues upstream of theGPI-attachment signal was removed and replaced with a hexa-His-tag,three glycosylation sites were disrupted by a serine to alanine mutation(S83, S102 and S126) and the N-terminal signal sequence left intact. Thecodon modifications implemented by CODOP are documented in Table 2 andthe entire synthetic gene sequence is shown in FIG. 6.

MSP5 codon usage of 3D7 and synthetic gene Codon aa p.f H5 GCA Ala 2 1GCC 2 2 GCG 0 1 GCT 0 3 total 4 7 AGA Arg 6 2 AGG 0 2 CGA 0 0 CGC 0 2CGG 0 0 CGT 1 1 total 7 7 AAC Asn 2 44 AAT 42 0 total 44 44 GAC Asp 2 13GAT 13 2 total 15 15 TGC Cyc 0 4 TGT 7 3 total 7 7 CAA Gln 5 4 CAG 1 2total 6 6 GAA Glu 23 23 GAG 6 6 total 29 29 GGA Gly 6 5 GGC 0 3 GGG 0 0GGT 6 4 total 12 12 CAC His 0 9 CAT 4 1 total 4 10 ATA Ile 10 0 ATC 1 10ATT 5 6 total 16 16 CTA Leu 3 2 CTC 0 7 CTG 0 2 CTT 2 2 TTA 10 1 TTG 2 3total 17 17 ATG Met 6 6 total 6 6 AAA Lys 15 5 AAG 3 13 total 18 18 TTCPhe 1 6 TTT 5 0 total 6 6 CCA Pro 4 3 CCC 0 3 CCG 0 0 CCT 5 3 total 9 9AGC Ser 3 5 AGT 7 8 TCA 8 3 TCC 1 4 TCG 1 1 TCT 5 1 total 25 25 TAA stop0 1 TAG 0 0 TGA 0 0 total 0 1 ACA Thr 2 0 ACC 1 2 ACG 2 0 ACT 1 4 total6 6 TGG Trp 0 0 total 0 0 TAC Tyr 0 7 TAT 7 0 total 7 7 GTA Val 3 2 GTC1 4 GTG 1 2 GTT 4 1 total 9 9 Codons 247 254 % GC 45.8

PCR assembly of the PfMSP5 synthetic gene was performed as previouslydescribed and due to the absence of repeat motifs within the sequencegenerated a highly pure end product (FIG. 7). The PCR product wasgel-extracted, cloned into pMOSBlue and sequenced before beingtransferred to the pVL1393 vector for integration into the Baculoviralgenome (Baculo-gold, Stratagene).

The constructs thus prepared were evaluated, and the results arereported in the following Examples.

Example 1 Expression of PfMSP4 in Insect Cells

After generating virus, using standard procedures [36], trial infectionswere performed in 150 cm² culture flasks (Corning). Infections wereperformed at a viral multiplicity of 10 for 1 h. Supernatants wereharvested after 3 days and batch purified over talon resin. Proteinproducts of the predicted size were seen with constructs MSP4p40/His (40kDa) and MSP4p30/His (30 kDa), but no protein was seen with constructMSP4-EGF/His (discussed further below). Expression of MSP4p21/His isstill in preliminary stages of analysis.

Production of both MSP4p40 and MSP4p30 was scaled up and moved fromboxes to spinner flask culture. To optimize protein yields and limitproduct degradation (frequently seen under the more aggressiveconditions of the spinner), a time course experiment was conducted.MSP4p40/His or MSP4p30/His infected spinner cultures (210 mL) were setup for both Spodoptrea frugiperda (SF9) insect cells and High Fiveinsect cells. Samples (8 mL) were collected at 24 h, 30 h, 36 h, 42 h,48 h, 54 h, 60 h and 72 h, analysed microscopically for cell deathstatistics and then dialysed against 20 mM Tris HCl (pH8); 500 mM NaCl.Proteins were purified over talon resin using a test tube protocol, andeluted into 100 μL of 100 mM imidazole; 20 mM Tris HCl (pH8); 500 mMNaCl. Percentage cell death over time was plotted for each infection anda 20 μsample of each elution was resolved in parallel for bothconstructs and cell types (FIG. 8).

As expected the High five cells generated far higher protein yields thanthe SF9 cells. However, it was observed that after long expressionperiods (more than 48 hrs) when protein degradation had begun, the MSP4protein did not degrade completely, but rather degraded into a smaller,stable product of approximately 20 kDa (MSP4p20). This product was alsoseen in later stages of the MSP4p30 infection. Since all protein waspurified via the C-terminal his-tag, this product must include theEGF-like domain and some up stream sequence forming a tight structurethat is resistant to protease. This agrees with finding of Wang et. al.(2001) [13], that the region upstream of the EGF-like domain harboursreduction sensitive B-cell epitopes.

Example 2 N-terminal sequencing and Mass Spectrometry

Using the information obtained from the time course experiment, threedifferent pure MSP4 protein preparations have been generated bycollecting the culture SN at different time points. Firstly, the fulllength MSP4, denoted MSP4p40, secondly, the full length modifiedproduct, MSP4p30, and thirdly, the breakdown product MSP4p20. Averageprotein yields for each product in standard High Five spinner culturehas been found to be 8 mg/L, 6 mg/L and 15 mg/L respectively, andreflects the time of harvest, with products harvested at earlier timepoints yielding less protein. In light of recent developments made incommercial Baculovirus competence (Henogen) it is believed that theseyields are minimal estimates

N-terminal sequencing of each product generated a strong and clearsignal (p40: starting at residue 41-MRILG, p30: starting at residue41-MRILA, p20: starting at residue 132-KSPKE) and revealed that the invivo P. falciparum signal sequence may in fact be twice as long (40residues as opposed to 20) as that predicted by PlasmoDB(http://plasmodb.org/plasmodb/servlet/sv?page=gene& source_id=PFB0310c).The identity of MSP4p40 and MSP4p20 has also been confirmed by MassSpectrometry, and the proteins have—actual molecular masses of 23.554kDa and 13.714 kDa, respectively.

The N-terminal sequence of the baculovirus-expressed MSP4 likelyidentifies the signal sequence used by the parasite. Firstly, theMSP4-EGF/His construct contains the PlasmoDB predicted signal sequenceplus 3 downstream residues and was never detected in culture SN.Secondly, the N-terminal cluster of polymorphic sites identified withinthe Pfmsp4 gene starts at the 45th codon. As suggested by the analysisdocumented in Polson et al., 2005 [33] the region of the gene downstreamof codon 45 is the target of an effective immune response for which itwould appear to have evolved an evasion mechanism through balancingallelic types within the population (involving residues 52 and 74; seeFIG. 5). Thus it seems likely that the processed N-terminus of PfMSP4consists of 4 conserved residues that contribute to the signal sequencecleavage site (MRIL) followed directly by a cluster of polymorphic sitescapable of reducing the effectiveness of immune responses directedpreferentially to this more accessible region of the protein.

Example 3 Signal Sequence Hydrophobicity

To further corroborate that the signal cleavage site used for MSP4constructs by the Baculovirus-system reproduces natural cleavage, abioinformatics study was conducted looking at previously reportednatural P. falciparum signal sequences. In 2001 a study was publishedcomparing known P. falciparum signal sequence cleavage sites [37]. Dueto the technical difficulties involved in obtaining such data, only 10such sequences exist. For the purposes of this study, eighty residues ofprotein sequence, centered around the reported signal sequence cleavagesite, of each protein were chosen and submitted (via the Pasteur server)to calculate values of local hydrophobicity. The hydrophobicity profileof three protein cleavage sites reported in Nacer 2001 and that ofMSP4p40 in the baculovirus-system are shown in FIG. 10. In the toppanel, both the KAHRP and MSP1 signal sequences display a classichydrophobicity profile, with cleavage occurring just after values ofhydrophobicity traverse the line of neutrality (positive to negative).It is known that the cleavage of the PfMSP1 signal is faithfullyperformed by the Baculovirus-system (Bonnet et. al. 2005). The samemarked change in local hydrophobicity if not present within theN-terminal of the MSP4p40 protein sequence at the predicted cleavagesite and cleavage actually occurs further downstream after the biggestlocal change in hydrophobicity (negative to positive). This profilematches that seen with the S-antigen and is thus not unique, addingweight to the finding that the MSP4p40 signal sequence is 40 residues inlength.

Example 4 Expression of PfMSP5 in Insect Cells

MSP5/His viral stocks were generated as previously described, and trialinfections and a time course study were conducted as described forMSP4p40/His. As shown in FIG. 11, three different PfMSP5 derivedproducts were detected migrating at approximately 45, 35 and 10 kDaunder SDS-page gel electrophoresis. Interestingly, the two largerproducts were seen to appear simultaneously during the early stages ofthe time course experiment, rather than the larger being generated andsubsequently degrading to form the smaller. Another striking differenceto the situation seen with PfMSP4 was the inversed protein productioncapabilities of the two cell lines studied, with SF9 cells far outperforming the faster growing and more fragile High Five cells. This initself was the first piece of evidence suggesting that PfMSP5 possessesvery different properties to PfMSP4. The second came from the N-terminalsequencing data.

Example 5 N-Terminal Sequencing and Mass Spectrometry

It has not been possible to obtain a signal for the N-terminal of thetwo largest products of MSP5 expression suggesting that they bothharbour an N-terminal modification that blocks the breakdown of thepeptide backbone, an essential event in N-terminal sequencing.Sequencing of the smaller 10 kDa product was successful and has definedthe N-terminal of this product to start at residue 189: YNKVE [SEQ IDNO: 26]. The identity of this product has also been confirmed by MassSpectrometry and it has an actual molecular mass of 7.746 kDa. Inaddition the sequence of the MSP5 viral genome has been confirmed andthe residues YNKVE [SEQ ID NO: 27] are only present in the correct ORF,thus these as yet undefined products must be PfMSP5.

The mass values obtained by MALDI-MS for the two largest MSP5 productsare 24.679 and 20.551 kDa, respectively, and did not match anypolypeptide derived from the MSP5 protein sequence alone, supporting theidea that these protein are carrying a post-transcriptionalmodification. To investigate possible N-terminal blocking modifications,the MSP5 sequence was submitted to prosite via the ExPASY home page.This revealed the presence of two N-myristoylation sites that coulddirect co-translational addition of a C14 fatty acid (at residue 42:GGFTSK and at residue 66: GSLPTK) [38]. However, while thesemodifications are exclusively N-terminal and could block N-terminalsequencing, they do not give rise to the appropriate mass values (24,015and 21,301, respectively). However, motif guided N-terminal modificationof glycine residues is not the only form of myristoylation that isperformed by eukaryotic cells. They can also post-transcriptionallymodify any N-terminal glycine and any lysine with a myristoyl group(review below). Working with these possibilities, close matches areobtained at 24.673 kDa and 20.553 kDa by assuming that each MSP5 product(p45 and p35) carries two fatty acid modifications, although theputative positions are at present undefined.

Example 6 Fatty Acid Modifications and Plasmodium

There are several different types of extra translational modificationthat are used by eukaryotic cells, including glycosylation,palmitoylation, N-myristoylation and myristoylation. Of these, the firstis not present in the MSP5 protein expressed here. All glycosylationsites were removed from the protein sequence during the construction ofthe synthetic gene, as it is known that this type of modification is notperformed by P. falciparum. The second type of modification is less wellunderstood in eukaryotes as a whole and it is believed thatpalmitoylation can occur via both enzyme dependent and enzymeindependent pathways [39]. To date there has been no report of anypalmitolyated P. falciparum proteins. However, protein N-myristoylationhas been shown to be important in Plasmodium. A PfN-myristoyltransferase gene homolog has been identified (PlasmoDBPF14_(—)10127) and found to be highly homologous to the human and yeastgene orthologues [40,41]. If this enzyme is as important to Plasmodiumas it is to other parasitic protozoa such as Trypanosoma brucei andLeishmania major, the N-myristoylation of multiple proteins can beexpected to be essential for parasite growth [41]. Indeed, N-terminalmyristoylation of PfADF (a ribosomal factor) has been shown to beimportant to mediate binding of GTP and facilitate enzyme activity [42].This fatty acid modification (both at an N-terminal glycine and aninternal lysine) has been shown to play a variety of roles in highereukaryotes involving the localization of proteins to membranes and thestabilization of protein-protein interactions [39, 43-45].

Example 7 In the Baculo-System

Since baculovirus infection of insect cells is a higher order eukaryoticsystem it is capable of performing many types of more evolved proteinmodification. Indeed, this system has been specifically employed togenerate several N-myristoylated proteins, the best described beingNAP-22 [46].

Example 8 Raising Antibodies

Rabbit polyclonal antiserum was generated by EUROGENTEC, using standardimmunization procedures, for recombinant MSP4p40, MSP4p20 and MSP5 (p45and p35). All rabbits were negative for MSP4 or MSP5 before immunization(two rabbits per antigen) and produced high titres of specific serumantibodies as determined by ELISA after 3 or 4 immunizations. Endpointtitres against reduced and non-reduced recombinant protein are shown inFIG. 12. As shown in panel B, recognition of MSP4p20 by antibodies fromrabbit No. 8 is reduced by more than 50% when the antigen is reduced,indicating that many of the epitopes of the MSP4p20 protein areconformational. Since reduction primarily affects disulfide bondedstructures, this data shows that the EGF-like domain of MSP4p20 isintact and involved in forming at least one B-cell epitopes.

Example 9 Parasite Derived MSP4

Preliminary immuno-blot data has been generated using the previouslydescribed polyclonal immune serum and is shown in FIG. 13. The data forMSP4 is in agreement with results published by the group of R. Coppel[9] where a 40 kDa protein is detected exclusively in the Triton X100solubilised fraction of late stage parasite preparations (FIG. 13A). Toinvestigate the properties of the C-terminal region of MSP4, MSP4p20, apool of rabbit sera (R6-9) and human sera collected in Dielmo, Senegalin 2002, were affinity purified against immobilized MSP4p20 (Amersham:NHS-activated Sepharose 4 fast flow). When asynchronous parasitematerial (separated by SDS-page and transferred to a nitrocellulosemembrane) was probed with these sera, in addition to the previouslyobserved band at 40 kDa, a band of approximately 18 kDa was also seen(FIG. 13B), suggesting that in natural infection the MSP4 antigen mayeither undergoes proteolytic processing similar to MSP1p42 or may bedegraded by proteases in a self-limiting fashion as obtained in thelater stages of baculovirus infection. To further confirm the naturalexistence of MSP4p20 epitopes on P. falciparum merozoites, an indirectimmunoflourescence assay (IFA) was performed on air-dried asynchronouslygrowing parasite cultures. Merozoite specific staining was seen with thehuman anti-MSP4p20, when no staining was seen with the secondaryantibody alone or with malaria naive sera (FIG. 13C).

Example 10 Parasite Derived MSP5

Immuno-blot data obtained using polyclonal sera raised againstbaculovirus expressed MSP5 shows a very different profile to thatpublished by other groups [9]. who have had apparent problems detectingMSP5 and suggest that it is expressed at low levels. Immuno-blot data ofthis invention show strong signals with antiMSP5 specific sera (FIG.13D). Unlike MSP4, parasite derived MSP5 is also present in the membranefraction of crudely prepared parasite extracts suggesting that it doesnot fractionate in a fashion consistent of a protein that is onlycarrying a GPI anchor. Indeed, when looking at reduced parasite materialit is possible to conclude that the polyclonal sera raised against theputatively N-myristoylated MSP5 can cross react with otherN-myristoylated proteins, further supporting the idea that this is aimportant and frequently used post-translational modification in P.falciparum.

Example 11 The Analysis of Human Immune Serum

To confirm that the protein products of the invention are recognized bythe antibodies of malaria-infected individuals, the sera of 9 randomlyselected semi-immune adults living in an endemic village in Senegal(Dielmo) were analysed by ELISA (FIG. 14). All individuals were positivefor all protein products (having OD values greater than control seraplus three times the standard deviation). Relative titres varied betweenindividuals and from product to product, but overall end point titreswere 1×10⁵ for MSP4 and 1×10⁴ for MSP5. Western blot analysis (FIG. 15)was performed using the sera from two individuals highly positive forMSP4 (individuals 3 and 9) and one individual highly positive for MSP5(individual 8). As previously seen with anti-MSP1p19, the humanantibodies to EGF-containing merozoite surface proteins has particularaffinity for aggregated material (FIG. 15).

Example 12 Anti-MSP4 Antibodies in Senegal; A Role in Protection

To further investigate a putative role for anti-MSP4 antibodies innatural infection, an epidemiological study was conducted. The threedifferent purified forms of MSP4, p40, p30 and p20, were evaluated intoa large prospective study that has been documented elsewhere (seereference [47]) and is detailed below in Example 16.

In summary, each form of the recombinant MSP4 protein was stronglyrecognized, with a sero-prevalence of >90%, but showed significantlydifferent mean IgG OD ratios (p40=20±10, p30=12.3±7.3 and p20 17.3±10).As seen with all malaria antigens, antibody titres increase with age andcorrelates of protection must be addressed using an age adjustedprogression model. Using this form of analysis anti-MSP4-p30 andanti-MSP4-p20 but not MSP4p40 antibodies were positively correlated witha reduced incidence of clinical malaria episodes (P=0.036, P=0.018+0.067respectively). These findings reinforce the identification ofpotentially balancing polymorphisms within the N-terminal region of MSP4protein [33] and more specifically support the concept of deleting thisregion of the protein in MSP4 based vaccine constructs.

Example 13 Anti-MSP5 Antibodies in Senegal; A Role in Protection

To further investigate the role of antiMSP5 antibodies in naturalinfection, an epidemiological study was conducted. A preparationcontaining the two high molecular weight forms of MSP5 was analyzed asdescribed elsewhere (see reference [47]).

While sero-prevalence was lower for MSP5 than for MSP4 (59%), a highlysignificant statistical correlation with reduced numbers of clinicalmalaria episodes was observed using the age adjusted progression model(P=0.0028). As discussed previously, this antigen may carry a fatty acidmodification with potential implications for lipid inducedimmunogenicity and immune responses in anti-infection immunity, as seenfor GPI modifications [48]; Bonnet et al 2005, publication inpreparation.).

In summary, PfMSP4 has a C-terminal EGF-like domain and is bound to themerozoite surface by a GPI anchor. Its function, although unknown,appears to be essential for parasite survival, since no viable PfMSP4“knock-out” mutants have been observed. Three recombinant PfMSP4constructs have been expressed as soluble, secreted proteins in thebaculovirus-insect cell expression system, to optimize reproduction ofthe native antigen, including proper folding of the EGF-like domain. Twoconstructs correspond to the MSP4 exo-antigen (minus C-terminalhydrophobic residues to permit secretion), with or without the deletionof 30 amino acids from a polymorphic region near the N-terminus(MSP4p30) and MSP4p40, respectively. A third 20 kDa protein correspondsapproximately to the C-terminal half of MSP4 including, the EGF domain(MSP4p20). Expression of this antigen in a more direct fashion is beingevaluated using the previously described construct MSP4p21/His.Anti-MSP4 antibody responses to the 3 different antigens were comparedwith regard to naturally acquired immunity in humans exposed to malaria,in a cross-sectional study of 205 individuals living in a mesoendemicvillage where transmission is seasonal.

Before the transmission season, the 3 constructs were stronglyrecognized: with a sero-prevalence >90%, but with significantlydifferent (P<0.01) mean IgG OD ratios of 20±10, 12.3±7.3 and 17.3±10 forMSP4p40, MSP4p30 and MSP4p20, respectively (approx. titres 5×10⁻³).Antibody responses to the MSP4 constructs were age-associated withindividuals <15 yr. old having significantly lower IgG levels thanadults (P<0.001, Rho 0.25-0.33). Analysis of clinical attacks during thesubsequent six-month period, including the transmission season, in anage-adjusted model, showed that the presence of IgG responses to MSP4p30and MSP4p20, both lacking the polymorphic region, but not MSP4p40 withthe polymorphic region, was significantly associated with a reducedincidence of malaria clinical episodes (P<0.05, rate # 0.75). Together,these results indicate: (i) there is a strong naturally acquired IgGresponse to PfMSP4, monitored using the baculovirus recombinant antigen;(ii) anti-MSP4 IgG correlates with protection against clinical malaria,and; (iii) the IgG response to the variable region, may interfere withotherwise protection-associated anti-MSP4 IgGs.

Example 14 PfMSP4 Monoclonal Antibodies

Four monoclonal antibodies (mAb) specific for PfMSP4 recognize 3different epitopes.

Monoclonal antibody L11-16 is representative of 2 others induced by p40(complete PfMSP4 polymorphic ecto-domain). Its reduction insensitiveepitope (17B) is located in the N-terminal half of PfMSP4 (non-p20;16A). It is particularly reactive with heterogeneous aggregates ofPfMSP4, the formation of which are reduction sensitive (FIG. 16A), andserves to demonstrate that high molecular weight material in non-reduced(nR), and partially reduced (R) SDS-PAGE is indeed PfMSP4 (as seenpreviously for baculovirus PfMSP1p19).

Monoclonal antibody F12-7 was induced by PfMSP4 p30 (lacking thepolymorphic region) and recognizes a reduction insensitive epitope inthe p20 C-terminal half of PfMSP4 (FIGS. 16B and 17B). Its apparentreduced reactivity with aggregates compared to L11-16 may be due to itsconsiderably lower affinity:

Clone Isotype KD/MSP5 epitope L11-16 Ig G1 3.2 10⁻⁹ M A F12-7 Ig G1 1.010⁻⁷ M C

Example 15 PfMSP5 Monoclonal Antibodies

Seven monoclonal antibodies (mAb) specific for PfMSP5 (p45+p35)recognize 5 different epitopes.

Monoclonal antibody G21-2 recognizes both the p45 and p35 PfMSP5products (FIG. 18A) and its epitope is not reduction sensitive (FIGS.18A and 19A). It reacts with discrete higher molecular weight aggregates(FIG. 18A, nR), the formation of which are reduction sensitive (FIG.18A, R).

Monoclonal antibody J18-14 recognizes only the p45, and its epitope isreduction sensitive (FIG. 19B). It is also reactive with aggregates.

Since these antigens were purified via a C-terminal hexahistidine tag,the p45 and p35 are thought to differ on the N-terminus. Thesecharacteristics suggest that the J18-14 epitope may correspond to aconformational structure involving both the C-terminal EGF domain andthe N-terminus. Both mAbs have similar affinities:

Clone Isotype KD/PfMSP5 epitope G21-2 Ig G1 2.8 10⁻⁸ M B J18-14 Ig G14.2 10⁻⁸ M D

The reactivities of these 2 mAbs can be used to define the PfMSP5product.

Example 16 Immune Sera and Cohort of Exposed Individuals

The following results were obtained using (A) a control pool ofhyper-immune sera taken from individuals living in endemic areas who donot manifest disease symptoms (B) individual sera from the village ofDielmo (holo-endemic transmission) collected in June 2005 and (C) acohort of 205 sera collected in the village of Ndiop (meso-endemictransmission) in July and August 2000 before the beginning of thetransmission season. The cohort included 108 males and 97 femalesbetween the age of 3 and 75 yrs old. Clinical accesses were activelyrecorded during the 5 following months and a total of 278 clinicalepisodes were treated (Perraut et al, JID 2005 191 264-271).

Analysis Protocol

(1) Optimization of antigen coating (2) selection of standard seradilution to be tested (3) systematic analysis of a cohort of sera (4)calculation of the median OD ratio value (5) stratification of theresults by age (6) functional analysis of select sera for invasion andgrowth inhibition (7) iso-typing for a select group of sera (8)statistical analysis of results, stratified as a function of the medianOD ratio, against clinical episode data.

(1) Calibration: Testing a dilution series of “sera hyper immune” (SHI)and selected individuals from the village of Dielmo (2005) using 2antigen coating concentrations of 1 and 0.5 μg/ml.

RESULT: Coating with 0.5 μg/ml was found to be optimal as the resultswere the same as seen with 1 μg/ml of antigen for individuals from bothvillages and the SHI. The responses of selected individuals werestronger in Dielmo than Ndiop and MSP5 showed lower magnitude Abresponses than MSP4. See FIGS. 20A and 20B.

(2) Calibration: Titration of SHI and positive serum from Dielmo

RESULTS: Referring to FIGS. 21A, 21B, 21C, and 21D, when using serumfrom Dielmo (60605), anti-MSP4 responses were highly positive (>SHI).However, the OD's were relatively low compared to the OD's obtainedlater with the Ndiop cohort of 2000, nevertheless, the titres of the SHIwere comparable. It would appear at first glance that the Ab's detectedhave a relatively low affinity as shown by the sharp angle of the curves(compared to those against MSP1 from previous studies)

SHI titre against MSP5= 1/1600

-   -   MSP4-40−MSP4-30−MSP4-20= 1/3200

(3) Analyses of the Ndiop Cohort 2000: Primary Results

The SHI was systematically titrated in each assay. OD ratios werecalculated with respect to the SHI control series on each plate. Forthis cohort, the OD ratios at 1/200 dilution were all high, although theactual titres were average (OD ratio values of between 4-6 give endpoint titres of around 1/2000)

(Result Below)

Results of titres/OD ratio MSP5 MSP4 K40 MSP4 K20 MSP4 MOD II SHI 60605SHI 60605 SHI 60605 SHI 60605 calib2 OD_r 4.0 13.6 31.0 36.1 14.9 30.019.1 29.5 titre 1600 6400 6400 25600 6400 25600 6400 25600 calib 1 OD_r5.1 36.8 22.5 26.1 titre 3200 12800 3200 12800 Ndiop_00 OD_r 6.6 28.424.4 18.6 titre 1600 12800 6400 12800(4) Incidence of responders

In the following table are shown the characteristics of the Ab responsesfrom the cohort of individuals from Ndiop 2000.

Positive responders were considered with an OD ratio of greater than

2. As shown below, MSP4 was recognised by almost all individuals (>90%)and MSP5 recognition was substantially lower (approx. 60%).

Statistiques descriptives n = 205 MPS4-20 MSP4-40 MSP4-mod2 MSP5 DO rtDODO rtDO DO rtDO DO rtDO Statistiques descriptives n = 205 MPS4-20MSP4-40 MSP4-mod2 MSP5 DO rtDO DO rtDO DO rtDO DO rtDO Moy 1.30 16.81.50 19.9 1.28 12.3 0.38 3.9 Médiane 1.33 17.3 1.83 24.3 1.35 12.9 0.212.4 Dév. Std 0.82 10.0 0.78 10.0 0.80 7.3 0.45 3.8 Minimum 0.02 1 0.02 10.01 1 0.01 1 Maximum 2.63 32.4 2.47 32.2 2.72 26.9 2.63 23.2 incidencerep 94% 97% 90% 59% incid <15 ans 89% 93% 80% 49% incid >15 ans 98%100%  97% 66%(5) Correlation with age and with other anti-MSP responses

Referring to FIGS. 22A, 22B, 22C, and 22D, there was a significantcorrelation with other anti-MSP responses

With MSP1 significant Rho # 0.27-0.36

Between various MSP4 antigens Rho >0.9

Between MSP4 and MSP5 Rho # 0.44-0.47

There was a significant correlation with age of individuals in the Ndiopcohort (P<0.001, Rho from 0.33 to 0.22), however, slightly less markedthan with MSP1. The anti-MSP5 Ab response was the least correlated withage, but individuals <15 yrs old had significantly lower level of Ab.

Focusing on MSP4: Differences in MSP4 Antigens

Referring to FIG. 23, there are highly significant differences in thelevels of recognition of the different fragments of MSP4 (P<0.001).Paradoxically, the smallest and biggest antigens (p20 and p40) arebetter recognized than the antigen MSP4-30 (or MSP4md2), which itself isonly 30 residues smaller than the full-length MSP4 (MSP4-40). Thisresult is interesting, as it seems to correspond with the existence ofan immune evasion strategy, where antibody responses are focalizedagainst the variable domains. This could explain the absence of acorrelation between IgG responses and invasion inhibition (see below).

(6) Relationship to Functional Tests

Referring to FIGS. 24A and 24B, there is not a significant difference ingrowth or invasion inhibition on the basis of a dichotomised comparisonbetween median OD ratio values for MSP4p40, MSP4p20, MSP4_mod (p30)(<20>) or MSP5 (<2.4>). (This property appeared only to be statisticallysignificant for anti-MSP1p19 Ab's in this cohort). However, there is asignificant difference regarding merozoite phagocytosis. This functionalcorrelate with merozoite phagocytosis was expected, as this phenomenonis associated with an overall increase in specific Ab titres (thus ODratio), which are known to increase as a function of age in endemicarea. See figure below:—

(7) Isotyping

Analysis was limited to a limited number of sera for MSP4-40 and MSP5.The results are shown in FIGS. 25A and 25B. For MSP4-p40 the isotypeprofile was IgG1+, IgG3+ and non-negligible amounts of IgG4:

-   -   There is no correlation between titres and recent circulating        parasitaemia    -   IgG3 levels were higher for individuals >15 yrs old (P=0.006)        and equal to those who had recently suffered malaria episodes        (P=0.03), which is an expected result as accesses is an age        related event in endemic area.    -   IgG1 and IgG3 were significant components of the IgG response,        representing 40% and 30% of the IgG respectively.    -   For the strong responders, there exists a significant        relationship between the IgG response and invasion inhibition        (IgG subclass independent).        For MSP-5, the isotype profile is predominantly IgG1    -   There is no difference in relation with recent circulating        parasitaemia (close to significance P=0.06) or with age.    -   IgG1 was a significant main component of the IgG response,        totalling 75% of the response.    -   There was no correlation between IgG response and invasion or        growth inhibition (no particular isotype was associated).        (8) Correlation with Malaria Episodes

An age-adjusted Poisson regression model was used to analyze therelationship between Ab responses against the Ag constructs and theincidence of malaria episodes during the follow-up period. Theseantigens showed a significant association with protection againstclinical episodes in the prospective study cohort of 205 individualsfrom the village of Ndiop (2000).

Concerning MSP4

In agreement with the previously noted observations, where significantdifferences were seen between IgG titres to MSP4-p40 and MSP4-p30, theAb responses against the full-length antigen (MSP4-p40) are notassociated with protection. However, Ab responses directed to theconstruct missing the 30 residue variable domain of the antigen(MSP4-p30) and the smallest antigen (MSP4p20) are significantlyassociated with protection (P<0.05). These findings reinforce the ideathat residue polymorphisms at the N-terminal of the protein are involvedin immune evasion and that antibodies directed to this region of theprotein have (A) limited affinity (B) exhibit strain specificity, thushave limited effect on a majority of strains or/and (C) due the presenceof APL never achieve affinity maturation or lack the required T-cellhelp. Regardless of the mechanisms involved, this data supports the ideathat conserved protein subunits have a better chance of inducing broadspecificity immunity than full entities, which frequently containregions of polymorphism believed to function in immune evasion.

Coef- Std. p- Rate Lower Upper ficient Error value Ratio (C.I.) (C.I.)MSP4-40 % GM −6.049 0.1935 <0.001 0.00236 0.001615 0.003449 AgeCl3 1.2150.1021 <0.001 3.37 2.759 4.116 m4 40cl2 −0.2279 0.1245 0.067 0.79620.6238 1.016 MSP4-30 % GM −6.031 0.1931 <0.001 0.002403 0.0016460.003508 AgeCl3 1.218 0.1017 <0.001 3.38 2.769 4.125 M4md cl2 −0.25460.1216 0.036 0.7752 0.6108 0.9839 MSP4-20 % GM −6.017 0.1914 <0.0010.002438 0.001676 0.003548 AgeCl3 1.216 0.1013 <0.001 3.373 2.766 4.114m4_20cl2 −0.2888 0.1223 0.018 0.7491 0.5895 0.9521episodes was found. In view of the fatty acid modification predicted tobe carried by the antigen, these results have interesting implicationswith regards to disease severity and anti-lipid responses.

Coef- Std. p- Rate Lower Upper MSP5 ficient Error value Ratio (C.I.)(C.I.) % GM −5.964 0.1917 <0.001 0.00257 0.001765 0.003741 AgeCl3 1.2010.1016 <0.001 3.324 2.724 4.057 msp5cl2 −0.3706 0.1243 0.0028 0.69040.541 0.8809

The primary conclusions that can be drawn from the above presented dataare (1) Baculovirus expressed MSP4 and MSP5 are useful as vaccines withactivities in line with those seen for MSP1p19, (2) these antigens arestrongly recognized by immune individuals (3) higher than median valuesof IgG recognition of the conserved domains of MSP4 (p30 and more sop20) and that of the highly conserved MSP5 antigen are correlated withnatural protection against clinical malaria.

Example 17 MSP4p20 Expression Constructs

Two constructs have been designed from Plasmodium falciparum MSP4synthetic gene sequence for the expression of MSP4p20. One construct isidentified as MSP4p21ss1 other named PfMSP4p21ss1 [SEQ ID NO: 28]. Theorf [SEQ ID NO:19] encoded by construct MPS4p21ss1 and the predictedamino acid sequence [SEQ ID NO: 20] are described below:

Nucleotide sequence of construct MSP4p21 ss1 >MSP4p21 ss1 [SEQ ID NO:28] ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATCTTGGGTGAAGAAAAGCTAACGTTGACGGTGTGTCAACATCTctaGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCACCACCACCATCACTAA ORF encoded by construct MSP4p21ss1 >MSP4p21 ss1 [SEQ ID NO: 19]MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRIL

EKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHHIn light grey: added amino acids directly following the residues MRIL inthe sequence of MSP4p40In dark grey: added amino acid L directly preceding the start of MSP4p20sequence in the sequence of MSP4p40

Expected protein product MSP4p21 ss1 [SEQ ID NO: 20]MRILGEEKPNVDGVSTSLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHHThe other construct is identified as MSP4p21 ss2 other named PfMSP4p21ss2 [SEQ ID NO: 29]. The orf [SEQ ID NO: 21] encoded by constructMPS4p21ss2 and the predicted amino acid sequence [SEQ ID NO: 22] aredescribed herein.

Nucleotide sequence of construct MSP4p21 ss2 >MSP4p21 ss2 [SEQ ID NO:29] ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATCTTGGGTGAAGAAAAGCCTCTAGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGGTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAAOAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCA CCACCACCATCACTAA ORFencoded by construct MSP4p21 ss2 >MSP4p21 ss2 [SEQ ID NO: 21]MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRIL

EKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKC KGKEGYKLEGIECVEHHHHHHIn light grey: added amino acids directly following the cleavage siteMRIL in the sequence of MSP4p40In dark grey: added amino acid L directly preceding the start of MSP4p20sequence in the sequence of MSP4p40

Expected protein product MSP4p21 ss2 [SEQ ID NO: 22]MRILGEEKPLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH

Example 18 Evolutionary Conservation of MSP4 Features

When the amino acid sequence of MSP4 from P. falciparum and P. vivax arealigned using a common alignment program (ClustalX) several strikingobservations can be made. See FIG. 26. Firstly, the residues downstreamof the signal sequence cleavage site of P. falciparum (as defined here)are nearly 100% conserved between the species (Pf MRILGE and Pv GRILGE).This finding once again strongly supports the idea that the maturePfMSP4 protein starts at residue 41 and the residues directly proceedingare part of a conserved cleavage site. Secondly, the sequence elementknown as SALSA (underlined) is not present in the P. vivax protein. Thiswould suggest that hepatocyte binding (if mediated by PfMSP4 in vivo) isnot a conserved, thus vital function of this protein. Instead thisregion of the P. vivax protein is completely divergent from that of P.falciparum and contains very low complexity sequence. While not visiblycomparable to the sequence of P. falciparum, one could imagine that theeffect on the immune system is similar. In P. falciparum, there is anN-terminal hyper-variable region at the extreme N-terminal of theprotein. Statistical analysis of polymorphism frequencies indicates twosites within this region that could be involved in immune evasion. Thiswould be achieved through the modification or ablation of B and T cellepitopes leading to strain specific responses and/or immune tolerancewhen exposed to variant sequences. This type of immune modulation isalso a property of repeat sequences. (A) They contain their own alteredpeptide ligands and (B) they can induce T-cell independent B-cellactivation which classically leads to the generation of short lived andlow affinity responses. The Third observation that can be made from thealigned sequences is that the primary sequence elements of the MSP4p20are present in both species. Unsurprisingly, both the core EFG-domainand GPI-attachments signals are conserved, more interestingly the acidicrepeats appear to be arranged in a comparable fashion. This lends weightto the idea that in natural infection MSP4 is either degraded or cleavedin a manor that leaves a membrane associated, small structural entity onthe surface of the merozoite. Whether this entity will enter the freshlyinvaded RBC, as seen with MSP1p19, has not yet been confirmed, but themodel seems to fit. On the bases of this comparison, the followingprotein sequence could be proposed as an anti-P. vivax malaria vaccinecandidate.

Example 19 Role of Antibodies to MSP4p20 in Antibody DependentPhagocytosis of Merozoites by Polymorphonuclear Neutrophils

Neutrophils internalize pathogens and destroy them using reactive oxygenspecies (ROS) and granule hydrolytic proteins. Activated neutrophils arehighly effective at generating ROS like O_(2′) ⁻, H₂O₂, . . . , by aprocess known as the respiratory burst operating via an NADPH oxydase.ROS can be detected by a chemiluminescence dye and used as a measure ofantibody induced phagocytic activity. The chemiluminescence dye isluminol, and in the presence of ROS, it emits light, which is quantifiedwith a luminometer (Microlumat+) linked to a computer.

Using a new functional assay based on antibody dependent phagocytosis ofmerozoites (ADPm) by polymorphonuclear neutrophils (PMN), phagocytosisof Plasmodium falciparum merozoites induced by naturally acquired andvaccination-induced antibodies was measured. Using immune sera fromindividuals in malaria endemic areas and frozen merozoite preparations,this test was shown to be highly specific, with negligible non-immunebackground signals, and good intra-assay reproducibility. Inter-assaycomparisons are made by using a standard positive control.

Data from individuals living in an area of seasonal transmission showedthat ADPm activity was significantly correlated with age and IgGantibody responses to merozoite and MSP recombinant antigens as measuredby ELISA. Depletion of antibodies specific for baculovirus recombinantMSP1p19 and MSP4p20 from endemic immune sera of residents of Dielmo andNdiop villages in Senegal, showed that antibodies against these antigensare substantial components of ADPm activity.

More particularly, P. falciparum merozoites were harvested bycentrifugation of culture supernatants and stored as frozen aliquots.Polymorpho-nuclear neutrophils, obtained from fresh donated blood, wereisolated with a simple Ficoll-Hystopaque 1077 gradient, and used in theADPm assay immediately. Endemic immune sera were obtained frominhabitants of Ndiop (mesoendemic) and Dielmo (holoendemic). RecombinantMSP1p19 and MSP4p20 antigens with C-terminal hexa-histidine tags wereproduced in the baculovirus expression system and purified byimmobilized-metalo-affinity chromatography. Sera were depleted ofanti-MSP1p19 or/and anti-MSP4p20 antibodies using a TALON metal affinityresin charged with the corresponding recombinant antigens. Merozoiteswere incubated with sera in 96-well plates before addition of luminoland PMN (5.10⁶ cells per well) to initiate the reaction. Luminescenceoutput was measured for 1 hour using a Berthold MicroLumat Plus 96wells. A positive standard human immune sera control (HIS) was used toquantify the response:

Antigen-specific IgG opsonisation (binding) of merozoites (with orwithout the complement) is required for a positive readout in thisassay, since decomplemented sera (treatment at 56° C. for 30 minutes) ortotal IgG purified with protein-G induces a similar response to theinitial sera, and serum depleted of total IgG no longer produces aresponse (FIG. 34). However, the magnitude of the chemiluminescenceeffect generated by specific IgG is variable. The FIG. 35 shows thatantibodies specific for baculovirus MSP4p20 and MSP1p19 are bothfunctional in this assay, but not to the same extent. Thechemiluminescence signal is reduced 67% following MSP4p20 antibodydepletion, compared to 34% reduction by MSP1p19 antibody depletion.Depletion of antibodies specific for both MSP4p20 and MSP1p19 reducedthe chemiluminescence signal by 78%.

These results show that natural antibodies recognizing the baculovirusMSP4p20 and MSP1p19 recombinant proteins are important componentsmediating merozoite phagocytosis and destruction by PMN immuneeffectors, strongly supporting the use of these antigens as vaccines.

Example 20 PfMSP5 Modification

To look at the nature of the N-terminal blocking modification seen to bepresent on Baculovirus expressed PfMSP5, radiolabelling experiments wereperformed. Since mass spectrometry suggested that the entity was acovalently associated myristoyl group, incorporation of Myristoyl wasinitially examined. Insect cell infections were performed in T25 cellculture flasks using SF9 cells as previously described in Example 1. At24 h post infection, 200 μCi of [9,10_((n))-³H] Myristic acid (Amersham)in complex with fatty acid free BSA was added to the culturesupernatant. At 70 h post infection, culture supernatants wereharvested, dialysed against 20 mM Tris pH8; 500 mM NaCl, and batchpurified over Talon® resin. On blue stained SDS-PAGE gels, proteinexpression was seen to be identical for the non-labelled control and theculture performed in the presence of radiolabel. When analysed byautoradiography, both PfMSP5 Baculovirus expressed proteins (35 and 45kDa) had incorporated the tritiated myristoyl (FIG. 27). No backgroundactivity was seen with un-labelled protein, and the two PfMSP5 proteinbands were not seen with the null virus infection.

These results show that recombinant PfMSP5 protein expressed inbaculovirus is myristoyled. These data confirm the previous data inExamples 4 to 7 related to expression of PfMSP5 in insect cells.

Example 21 The Fate of PfMSP4

To follow the natural fate of PfMSP4, several different purified serawere generated. Firstly, a pool of anti-sera collected from 4MSP4-vaccinated rabbits was affinity purified against NHS-activatedsepharose fixed Baculovirus expressed PfMSP4p20. This process wasrepeated using two different pools of 5 human immune sera known to bepositive for PfMSP4 from either Ndiop or Dielmo. Using these antibodyreagents, the fate of PfMSP4 was followed by IFA and western blot in theculture adapted strain 3D7 and the finding was compared to those seenwith a monoclonal antibody specific for PfMSP1p19 (G17.12). As shown inFIG. 28A, PfMSP4 was detected at the surface of late stage parasites andfree merozoites but not in acetone fixed ring stage parasites in whichPfMSP1p19 could be identified. In addition, when looking at parallelanalysis of equal quantities of parasite extract by western blot (FIG.28B), PfMSP4 levels seem to be far less on free merozoites collectedfrom parasite culture supernatants than on mature schizonts and theprotein is not detected in ring stage parasite extracts. This data isconsistent with the idea that PfMSP4 is shed from the merozoite surfacein a manner similar to Apical Membrane Antigen-1 rather than beingproteolytically processed and carried into the freshly invaded RBC, asseen for MSP1p19.

Interestingly, both affinity-purified sera (rabbit and human) recognisemultiple high molecular weight protein bands exclusive to the matureschizont extract. This could be antigens present in the mature schizontthat contain cross-reactive epitopes as previously found with MSP3 andMSP6, or, since the parasite extract is not reduced, this could benatural PfMSP4 protein trimers.

To investigate PfMSP4 expression in pre-hepatic stage parasites, IFA wasperformed on P. falciparum sporozoites using anti-PfMSP4p20 affinitypurified rabbit sera. While the positive control anti-CSP monoclonalantibody gave strong and clear surface staining, no staining wasachieved with the anti-PfMSP4p20 antibodies.

These results show that natural MSP4 protein is localized on merozoite'ssurface and is no more present upon reinvasion of blood cells by theparasite (see IFA on ring-stage infected blood cells, FIG. 28A). Thewestern blot of FIG. 28B shows identical patterns with antibodiesdirected against natural MSP4 (human sera) and with antibodies directedagainst recombinant MSP4 (rabbit sera). So it can be deduced from thisthat antibodies directed against baculovirus recombinant antigen areable to recognize natural forms of antigen.

Example 22 Expression of the p20 Sub-Domain Independently of p40

To facilitate direct expression of the p20 sub-domain, a series of newexpression constructs were built (FIG. 29 and Example 17) and tested. Asshown in FIG. 30, the construct encoding the minimum signal sequence(PfMSP4p21) did not lead to protein secretion, though high levels ofintracellular protein were detected (data not shown). Better levels ofexpression were achieved with constructs PfMSP4p21ss1 and ss2 and asseen in FIG. 30, and as revealed by N-terminal sequencing (see FIG. 29),both proteins rapidly lose the remaining N-terminal residues to producethe same stable p20 entity that is seen with baculovirus PfMSP4p40.However, when comparing protein expression at 66 h post infection fromparallel infections conducted using baculovirus PfMSP4p40 andPfMSP4p21ss1, the original construct leads to far superior proteinyields (2-fold). These results complement Example 17, supra.

Example 23 Expression of PvMSP4 in the Baculovirus Expression System

To obtain the PvMSP4 open reading frame (ORF), nested PCR was performedon genomic DNA from the parasite strain Belem. As P. vivax genomic DNAis around 50% GC rich, it was not necessary to make a synthetic gene.The entire ORF was cloned into pMosBLUE and sequenced. Next, both exonswere amplified by PCR with the GPI attachment signal at the 3′ end ofexon 2 replaced by a hexa-his tag. In addition, a suitable restrictionsite was introduced at the 3′ or 5′ end of exon 1 and 2, respectively,and these were sequentially cloned into the pMosBLUE vector to form acontinuous ORF ending in a his-tag (FIG. 31).

A PvMSP4 encoding Baculovirus was generated using the standard protocoland protein expression over time was assessed using High Five insectcells as previously described. As shown in FIG. 32, protein expressionwas detectable at around 30 h post infection.

N-terminal sequence analysis performed on this protein band revealed anN-terminal of GIAAC. Protein expression peaked at around 54 h postinfection and at this time point some protein degradation was visible.However, PvMSP4 does not degrade in a manner similar to PfMSP4.N-terminal sequencing of the final product showed that the protein haddegraded by 13 or 30-32 amino acids giving the N-terminal sequence ofEGGEQ and a mixed signal giving GDSSG, DSSGG and SSGGL. The smallestprotein product detected, around 8 kDa in size, carries the N-terminalsequence LDNNG.

Example 24 Human Immune Sera Recognition of PvMSP4

At the end of the time course analysis (66 h as shown in FIG. 32) 130 mLof culture supernatant was purified by HPLC over Talon resin. Thepurified product consists of the 30, 25 kDa, and 8 kDa bands seen inFIG. 32.

To look at human sera recognition, ELISA plates were coated with theBaculovirus expressed PvMSP4 at 0.5 μg/mL.

A total of 24 Sera samples collected in Sri Lanka from individualshaving experienced at least one episode of P. vivax malaria, were testedin parallel. Seventeen of these samples were sera positive for PvMSP4with end-point titre of between 1/25,000 and 1/200,000 (FIG. 33A). Theseseventeen positive sera were tested at 1/2700 dilution on ELISA platescoated with baculovirus PvMSP4 irreversibly reduced by treatment withDTT and iodoacetamide. Of the 17 positive sera, 11 showed a degree ofreduction sensitivity ranging from 12-80% whether calculated at a fixeddilution of 1/2700 or using the dilution falling in the mid point ofeach curve (FIG. 33B).

Examples 23 and 24, relating to Plasmodium vivax MSP4 (PvMSP4),complement Example 18. As shown in FIG. 33B, while sera No 2, 3, 4, 6,7, 8, 9, 10, 11, 14, and 17 have less affinity for DTT-reduced antigenthan for non-reduced antigen, sera Nos. 12 and 15 have a better affinityfor reduced antigen than for the non-reduced one. It can be concludedthat antigen conformation affects antibody-antigen binding, but, theprotective capacity of each of the tested sera against a Plasmodiuminfection being not established, antibodies affinity for reduced ornon-reduced antigen can not be correlated with the protective value ofthe two types of antibody.

The following PfMSP5/His, PfMSP4p30/His and PfMSP4p40/His baculoviruswere deposited at the Collection Nationale de Cultures deMicroorganismes (C.N.C.M.), of Institut Pasteur, 28, rue du DocteurRoux, 75724 Paris, Cedex 15, FRANCE, on Nov. 10, 2005, and assigned thefollowing Accession Nos.

MATERIAL ACCESSION NO. PfMSP5/His I-3512 PfMSP4p30/His I-3513PfMSP4p40/His I-3514

The following F12-7, G21-2, J18-14 and L11-6 hybridomas were depositedat the Collection Nationale de Cultures de Microorganismes (C.N.C.M.),of Institut Pasteur, 28, rue du Docteur Roux, 75724 Paris, Cedex 15,FRANCE, on Nov. 16, 2005, and assigned the following Accession Nos.

MATERIAL ACCESSION NO. F12-7 I-3517 G21-2 I-3518 J18-14 I-3519 L11-16I-3520

The following PfMSP4p21ss1/His, PfMSP4p21ss2/His, and PvMSP4/His weredeposited at the Collection Nationale de Cultures de Microorganismes(C.N.C.M.), of Institut Pasteur, 28, rue du Docteur Roux, 75724 Paris,Cedex 15, FRANCE, on Nov. 21, 2006, and assigned the following AccessionNos.

MATERIAL ACCESSION NO. PfMSP4p21ss1/His I-3695 PfMSP4p21ss2/His I-3696PvMSP4/His I-3694

Following are amino acid and nucleic acid sequences of peptides andpolynucleotides described, supra:

MSP5p10 (breakdown product of MSP5, residue 186-253) [SEQ ID NO: 16]YNKVEKNVTDEMLLYNMMSDQNRKSCAINNGGCSDDQICININNIGVKCI CKDGYLLGTKCIHHHHHHNucleic acid sequence encoding MSP5p10 >readseq-48009_tmp_1 207 bp [SEQID NO: 5] TACAACAAGGTCGAGAAGAACGTAACCGACGAGATGCTCTTGTACAACATGATGTCCGACCAAAACCGCAAAAGCTGTGCTATCAACAACGGTGGCTGCAGTGACGACCAGATCTGCATCAACATCAACAACATCGGTGTGAAGTGCATTTGTAAGGATGGATACCTACTTGGTACCAAGTGCATTCACCACCACCACCA CCACTGA SEQ ID NO: 1= nucleic acid encoding breakdown product MSP4p20 of SEQ ID NO: 9(residue 132-251) >readseq-41112_tmp_1 363 bp [SEQ ID NO: 1]AAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCACCA CCACCATCACTAAMSP5 >readseq.input(1), 762 bases, 6761DE71 checksum. [SEQ ID NO: 4]ATGAACATTCTCTGTATTCTCAGCTACATTTACTTCTTCGTGATCTTCTACAGTTTAAACCTCAACAACAAAAACGAGAACTTCTTGGTGGTCCGCAGACTCATGAACGACGAAAAGGGAGAAGGTGGCTTOACTAGTAAGAACAAGGAAAACGGAAACAACAACAGGAACAACGAGAACGAACTCAAAGAAGAAGGATGTTTGCCCACTAAGATGAACGAGAAAAACAGTAACTCGGCGGATAAGCAACCAAACGACATCTCCCACGACGAAAGCAAGAGCAACAGTAACAACGCCCAAAACATCGAAAAGGAACCTGAAGAGAAGGAAAAGTCAAACCCCAACCTCGACTCGAGTGAAAACTCCGCTGAAAGTGCTACTAGAAGCGTCGACATCAGTGAACACAACTCAAAGAACCCCGAAACTAAAGAAGAAAACGGAGAAGAACCTCTAGACCTGGAAATTAACGAAAACGGAGAAATCGGCCAGGAACCTCCAAACCGTCTTCACTTCGACAACGTTGACGACGAAGTACCACATTACTCAGCCCTGAGGTACAACAAGGTCGAGAAGAACGTAACCGACGAGATGCTCTTGTACAACATGATGTCCGACCAAAACCGCAAAAGCTGTGCTATCAACAACGGTGGCTGGAGTGACGACCAGATGTGCATGAACATCAACAACATCGGTGTGAAGTGCATTTGTAAGGATGGATACCTACTTGGTACCAAGTGCATTCACCACCAC CACGACCACTGA PROTEINENCODED BY ORF >readseq.input(1), 253 bases, 7870B947 checksum. [SEQ IDNO: 14] MNILCILSYIYFFVIFYSLNLNNKNENFLVVRRLMNDEKGEGGFTSKNKENGNNNRNNENELKEEGSLPTKMNEKNSNSADKQPNDISHDESKSNSNNAQNIQKEPEEKENSNPNLDSSENSAESATRSVDISEHNSNNPETKEENGEEPLDLEINENAEIGQEPPNRLHFDNVDDEVPHYSALRYNKVEKNVTDEMLLYNMMSDQNRKSCAINNGGCSDDQICININNIGVKCICKDGYLLGTKCIHHH HHHMSP4p40 >readseq.input(1), 756 bases, 733F5E48 checksum. [SEQ ID NO: 3]ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATCTTGGGTGAAGAAAAGCCTAACGTTGACGGTGTGTCAACATCTAACACACCTGGCGGAAACGAGGCATCTAGTGCTTCTCCTAACCTTGCTGACGCTGCAGAAAAGAAGGACGAAAAGGAAGCAAGCGAGCAAGGCGAAGAATCCCACAAGAAGGAAAACTCTCAGGAATCTGCAAACGGAAAAGACGACGTTAAGGAGGAGAAGAAGACCAACGAGAAGAAGGACGACGGAAAGACTGACAAGGTACAAGAAAAGGTTCTAGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGAGGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCACCACCACCAT CACTAA PROTEINENCODED BY ORF >readseq.input(1), 251 bases, 1EFAEF35 checksum. [SEQ IDNO: 12] MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILGEEKPNVDGVSTSNTPGGNEASSASPNLADAAEKKDEKEASEQGEESHKKENSQESANGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHH H FINAL PRODUCEDPROTEIN >readseq.input(1), 211 bases, 67EAFE8C checksum. [SEQ ID NO: 13]MRILGEEKPNVDGVSTSNTPGGNEASSASPNLADAAEKKDEKEASEQGEESHKKENSQESANGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKGKCkEGYKLEG IECVEHHHHHH P20PROTEIN secreted with the FINAL PRODUCTED PROTEIN >readseq.input(1), 120bases, 9358BD28 checksum. [SEQ ID NO: 9]KSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCK CKEGYKLEGIECVEHHHHHHMSP4p30 >readseq.input(1), 666 bases, A9B2DCBC checksum. [SEQ ID NO: 2]ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCcTGAAAACGGACGTATGCTTAACATGAGGATCTTGGCTGCAGAAAAGAAGGACGAAAAGGAAGCAAGCGAGCAAGGCGAAGAATCCCACAAGAAGGAAAACTCTCAGGAATCTGCAAACGGAAAAGACGACGTTAAGGAGGAGAAGAAGACCAACGAGAAGAAGGACGACGGAAAGACTGACAAGGTACAAGAAAAGGTTCTAGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCA CCACCACCATCACTAAPROTEIN ENCODED BY ORF >readseq.input(1), 221 bases, F982D7F0 checksum.[SEQ ID NO: 10] MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILAAEKKDEKEASEQGEESHKKENSQESANGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKC KGKEGYKLEGIECVEHHHHHHFINAL PRODUCED PROTEIN >readseq.input(1), 181 bases, FB2C49DD checksum.[SEQ ID NO: 11] MRILAAEKKDEKEASEQGEESHKKENSQESANGKDDVKEEKKTNEKKDDGKTDKVQEKVLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH MSP4p21 >readseq.input(1), 498 bases,C2453A47 checksum. [SEQ ID NO: 6]ATGTGGATCGTAAAGTTGTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAAGATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATTCTAGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGAGGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCACCACCACCATCACTAA PROTEIN ENCODED BYORF >readseq.input(1), 165 bases, 27BB4F2E checksum. [SEQ ID NO: 17]MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGY KLEGIECVEHHHHHH FINALPRODUCED PROTEIN readseq.input(1), 125 bases, 50D64DD2 checksum. [SEQ IDNO: 18] MRILEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH MSP4p21 ss1 >readseq.input(1), 540 bases,96DADE5 checksum. [SEQ ID NO: 7]ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATCTTGGGTGAAGAAAAGCCTAACGTTGACGGTGTGTCAACATCTctaGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACGACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACAGGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCAGCACCACCATCACTAA PROTEIN ENCODED BYORF >readseq.input(1), 179 bases, F0D6C58 checksum. [SEQ ID NO: 19]MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILGEEKPNVDGVSTSLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGGGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH FINAL PRODUCED PROTEIN >readseq.input(1),139 bases, 4D5C3EOF checksum. [SEQ ID NO: 20]MRILGEEKPNVDGVSTSLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH MSP4p21 ss2 >readseq.input(1),516 bases, 1B3CABBA checksum. [SEQ ID NO: 8]ATGTGGATCGTAAAGTTCTTGATTGTGGTCCACTTCTTCATCATATGCACCATCAACTTCGACAAGCTCTACATTAGTTACTCTTACAACATCGTCCCTGAAAACGGACGTATGCTTAACATGAGGATCTTGGGTGAAGAAAAGCCTCTAGAAAAGAGTCCCAAGGAGAGTCAAATGGTCGACGACAAGAAGAAGACCGAGGCCATTCCAAAGAAAGTCGTGCAGCCAAGCTCGAGCAACTCTGGAGGTCACGTCGGTGAAGAAGAAGACCACAACGAAGGAGAGGGAGAGCACGAAGAGGAGGAAGAACACGAAGAAGACGATGACGACGAGGACGACGACACATACAACAAAGACGACTTGGAGGACGAAGATCTTTGCAAGCACAACAACGGAGGATGTGGAGATGACAAGCTCTGCGAGTACGTTGGAAACCGTCGCGTAAAATGTAAATGTAAGGAAGGATACAAGTTGGAAGGAATTGAGTGCGTTGAACACCA CCACCACCATCACTAAEXPECTED PROTEIN ENCODED BY ORF >readseq.input(1), 171 bases, EB09D214checksum. [SEQ ID NO: 21]MWIVKFLIVVHFFIICTINFDKLYISYSYNIVPENGRMLNMRILGEEKPLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKC KCKEGYKLEGIECVEHHHHHHFINAL PRODUCED PROTEIN >readseq.input(1), 131 bases, 6B6B091D checksum.[SEQ ID NO: 22] MRILGEEKPLEKSPKESQMVDDKKKTEAIPKKVVQPSSSNSGGHVGEEEDHNEGEGEHEEEEEHEEDDDDEDDDTYNKDDLEDEDLCKHNNGGCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVEHHHHHH PvMSP4/His PROTEIN [SEQ ID NO: 16]MKVAYFLSVLDLLIIFSLYFDGRRSAFAGIAACIRHGRILGEGGEQSGGASGGSSGGSSGDSSGGLSGGSSGGPSPPAGSSGSGGSDPANSATGPQNSTPGSGGQTGDHSAEAENGDYNEQGDDHGDDHGDDHGDDHGDEQDGEDYDDAEDDDLYELSEVDENANLCLDNNGGCGDDKICENLGKGIVKCLCKPGYKLVG TECVESHHHHHH

Biological material disclosed as PfMSP5/His, PfMSP4p30/His,PfMSP4p40/His, PfMSP4p21ss1/His, PfMSP4p21ss2/His, and PvMSP4/His isdescribed in the present application, especially in the Examples. Itcomplies with the following requirements:

-   -   Requirements for propagating virus:        -   Cell type: Spodoptera frugiperda (Sf9)        -   Medium:        -   SF-900 II medium with L-Glutamine (GIBCO, Invitrogen            Corporation) Cat No. 10902-088        -   L-Glutamine 200 mM (GIBCO, Invitrogen Corporation): 2 mM            final concentration Cat No. 25030-024        -   Gentamicin (50 mg/ml, GIBCO, Invitrogen Corporation):        -   50 μg/ml final concentration Cat No. 15750-037            -   Serum        -   Fetal Calf serum 5%            -   pH 6,2            -   Temperature 27-28° C.            -   Gaseous phase: Ambiant (no CO₂ enrichment)    -   Method used for obtaining a virus suspension:        -   Details for propagating: a culture in a vessel (T-25, T-75            or T-150) with a monolayer of Sf9 cells in a fresh complete            medium (with 5% FCS) is inoculated with a small quantity of            viral suspension (or a plaque or a well of a microtitration            plate obtained from a cloning procedure by limiting            dilution). The culture is incubated at 27-28° C. until lysis            of all cells, around 5-6 days.        -   Criteria for evidence of infection: cells with extended            nuclei, followed by a granular aspect and cell lysis after            several days.        -   Details for preparing the virus suspension        -   Cell supernatant is centrifuged 10 minutes to 4000 g to            remove the cell debris    -   Method used for titration        -   Limiting dilution (1 well is infected starting from the            dilution giving rise to about 1/10 of positive microtiter            plate of 96 wells) The results have been read after 6 days            and the expected titer was 10⁷-10⁸ pfu/ml.    -   Conditions for storage        -   Long-term maintenance is enabled by freezing at −80° C. The            suspending fluid is a standard culture medium.

The above hybridomas F12-7, G21-2, J18-14, and L11-16 were obtained as aresult of a cell fusion between a mouse myeloma cell (plasmocytomeAg8×63 6.5.3) and a mouse immunocyte obtained from the spleen of theanimal immunized with the specified antigen.

-   -   Characteristics and products of the cells        -   Myeloma designation: X63-Ag8-6.5.3        -   Antigenic specificity: MSP4 II for F 12-7 MSP5 for G21-2 and            for 518-14, MSP4 for L11-16.        -   Antibody subclass: IgG1k        -   Stability of secretion: good and illimited    -   Conditions for cultivation:        -   Culture medium        -   Eagle MEM-Eurobio        -   Sodium pyruvate—Gibco BRL        -   Glutamine—Gibco BRL        -   Antibiotics: péni-streptomycine—Gibco BRL        -   Horse serum: 10%            -   Serum bicarbonate 2.2 g/l        -   Serum: horse 10%        -   pH7.4        -   optimal temperature: 37° C.        -   Gaseous phase: 7% CO₂            -   Precautions to be taken for thawing: rapidly defreezing                at 37° C., immediate washing in the medium+serum.                Culture on plate with 24 wells of 1 ml.    -   Conditions for cultivation: cell suspension        -   Population doubling time: 15 h        -   Optimal split ratio: 3 days        -   Expected cell density: 5.10⁶        -   Illimited lifespan        -   Technique for routine sub-culture: split    -   Conditions for storage        -   Suspending fluid: 95% horse serum-5% DM50 Technique for cell            harvesting: taking cell suspension, centrifugation and            pellet uptake in the freezing medium.        -   Technique for freezing: 5.10⁶ cells in 1 ml of freezing            medium—2 h at −20° C., 3 to 4 days at −80° C. and liquid            nitrogen. The suspending fluid is a standard culture medium.

REFERENCES

The entire disclosures of each of the following publications are reliedupon and incorporated by reference herein.

-   1 Genton, B., Al-Yaman, F., Betuela, I. et al. Safety and    immunogenicity of a three-component blood-stage malaria vaccine    (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New    Guinean children. Vaccine 2003, 22(1), 30-41.-   2 Stowers, A. W., Kennedy, M. C., Keegan, B. P., Saul, A.,    Long, C. A. & Miller, L. H. Vaccination of monkeys with recombinant    Plasmodium falciparum apical membrane antigen 1 confers protection    against blood-stage malaria. Infect Immun 2002, 70(12), 6961-6967.-   3 O'Donnell, R. A., de Koning-Ward, T. F., Burt, R. A. et al.    Antibodies against merozoite surface protein (MSP)-1(19) are a major    component of the invasion-inhibitory response in individuals immune    to malaria. J Exp Med 2001, 193(12), 1403-1412.-   4 Hughes, M. K. & Hughes, A. L. Natural selection on Plasmodium    surface proteins. Mol Biochem Parasitol 1995, 71(1), 99-113.-   5 Escalante, A. A., Lal, A. A. & Ayala, F. J. Genetic polymorphism    and natural selection in the malaria parasite Plasmodium falciparum.    Genetics 1998, 149(1), 189-202.-   6 Volkman, S. K., Hartl, D. L., Wirth, D. F. et al. Excess    polymorphisms in genes for membrane proteins in Plasmodium    falciparum. Science 2002, 298(5591), 216-218.-   7 Rayner, J. C., Corredor, V., Feldman, D. et al. Extensive    polymorphism in the plasmodium vivax merozoite surface coat protein    MSP-3alpha is limited to specific domains. Parasitology 2002, 125(Pt    5), 393-405.-   8 Taylor, R. R., Smith, D. B., Robinson, V. J., McBride, J. S. &    Riley, E. M. Human antibody response to Plasmodium falciparum    merozoite surface protein 2 is serogroup specific and predominantly    of the immunoglobulin G3 subclass. Infect Immun 1995, 63(11),    4382-4388.-   9 Wang, L., Mohandas, N., Thomas, A. & Coppel, R. L. Detection of    detergent-resistant membranes in asexual blood-stage parasites of    Plasmodium falciparum. Mol Biochem Parasitol 2003, 130(2), 149-153.-   10 Marshall, V. M., Silva, A., Foley, M. et al., A second merozoite    surface protein (MSP-4) of Plasmodium falciparum that contains an    epidermal growth factor-like domain. Infect Immun 1997, 65(11),    4460-4467.-   11 Wu, T., Black, C. G., Wang, L., Hibbs, A. R. & Coppel, R. L. Lack    of sequence diversity in the gene encoding merozoite surface protein    5 of Plasmodium falciparum. Mol Biochem Parasitol 1999, 103(2),    243-250.-   12 Wang, L., Black, C. G., Marshall, V. M. & Coppel, R. L.    Structural and antigenic properties of merozoite surface protein 4    of Plasmodium falciparum. Infect Immun 1999, 67(5), 2193-2200.-   13 Wang, L., Richie, T. L., Stowers, A., Nhan, D. H. & Coppel, R. L.    Naturally acquired antibody responses to Plasmodium falciparum    merozoite surface protein 4 in a population living in an area of    endemicity in Vietnam. Infect Immun 2001, 69(7), 4390-4397.-   14 Black, C. G., Wang, L., Hibbs, A. R., Werner, E. & Coppel, R. L.    Identification of the Plasmodium chabaudi homologue of merozoite    surface proteins 4 and 5 of Plasmodium falciparum. Infect Immun    1999, 67(5), 2075-2081.-   15 Black, C. G. & Coppel, R. L. Synonymous and non-synonymous    mutations in a region of the Plasmodium chabaudi genome and evidence    for selection acting on a malaria vaccine candidate. Mol Biochem    Parasitol 2000, 111(2), 447-451.-   16 Kedzierski, L., Black, C. G. & Coppel, R. L. Characterization of    the merozoite surface protein 4/5 gene of Plasmodium berghei and    Plasmodium yoelii. Mol Biochem Parasitol 2000, 105(1), 137-147.-   17 Kedzierski, L., Black, C. G., Goschnick, M. W., Stowers, A. W. &    Coppel, R. L. Immunization with a Combination of Merozoite Surface    Proteins 4/5 and 1 Enhances Protection against Lethal Challenge with    Plasmodium yoelii. Infect Immun 2002, 70(12), 6606-6613.-   18 Kedzierski, L, Black, C. G. & Coppel, R. L. Immunization with    recombinant Plasmodium yoelii merozoite surface protein 4/5 protects    mice against lethal challenge. Infect Immun 2000, 68(10), 6034-6037.-   19 Kedzierski, L., Black, C. G., Stowers, A. W., Goschnick, M. W.,    Kaslow, D. C. & Coppel, R. L. Comparison of the protective efficacy    of yeast-derived and Escherichia coli-derived recombinant merozoite    surface protein 4/5 against lethal challenge by Plasmodium yoelii.    Vaccine 2001, 19(32), 4661-4668.-   20 Wang, L., Goschnick, M. W. & Coppel, R. L. Oral Immunization with    a Combination of Plasmodium yoelii Merozoite Surface Proteins 1 and    4/5 Enhances Protection against Lethal Malaria Challenge. Infect    Immun 2004, 72(10), 6172-6175.-   21 Goschnick, M. W., Black, C. G., Kedzierski, L., Holder, A. A. &    Coppel, R. L. Merozoite Surface Protein 4/5 Provides Protection    against Lethal Challenge with a Heterologous Malaria Parasite    Strain. Infect Immun 2004, 72(10), 5840-5849.-   22 Marshall, V. M., Tieqiao, W. & Coppel, R. L. Close linkage of    three merozoite surface protein genes on chromosome 2 of Plasmodium    falciparum. Mol Biochem Parasitol 1998, 94(1), 13-25.-   23 Nishimura, Y., Chen, Y. Z., Uemura, Y. et al., Degenerate    recognition and response of human CD4+Th cell clones: implications    for basic and applied immunology. Mol Immunol 2004, 40(14-15),    1089-1094.-   24 Brady, C. P., Shimp, R. L., Miles, A. P., Whitmore, M. &    Stowers, A. W. High-level production and purification of    P30P2MSP1(19), an important vaccine antigen for malaria, expressed    in the methylotropic yeast Pichia pastoris. Protein Expr Purif 2001,    23(3), 468-475.-   25 Epp, C., Kauth, C. W., Bujard, H. & Lutz, R. Expression and    purification of Plasmodium falciparum MSP-1 (42): A malaria vaccine    candidate. J Chromatogr B Analyt Technol Biomed Life Sci 2003,    786(1-2), 61-72.-   26 Withers-Martinez, C., Saldanha, J. W., Ely, B. et al. Expression    of recombinant Plasmodium falciparum subtilisin-like protease-1 in    insect cells. Characterization, comparison with the parasite    protease, and homology modeling PCR-based gene synthesis as an    efficient approach for expression of the A+T-rich malaria genome. J    Biol Chem 2002, 277(33), 29698-29709. Epub 22002 June 29696.-   27 Zhou, Z., Schnake, P., Xiao, L. & Lal, A. A. Enhanced expression    of a recombinant malaria candidate vaccine in Escherichia coli by    codon optimization. Protein Expr Purif 2004, 34(1), 87-94.-   28 Weber, J. L. Molecular Biology of Malaria Parasites. Exp.    Parasitol. 1988, 66, 143-170.-   29 Withers-Martinez, C., Carpenter, E. P., Hackett, F. et al.    PCR-based gene synthesis as an efficient approach for expression of    the A+T-rich malaria genome. Protein Eng 1999, 12(12), 1113-1120.-   30 Ballou, W. R., Arevalo-Herrera, M., Carucci, D. et al. Update on    the clinical development of candidate malaria vaccines. Am J Trop    Med Hyg 2004, 71(2 Suppl), 239-247.-   31 Wang, L., Marshall, V. M. & Coppel, R. L. Limited polymorphism of    the vaccine candidate merozoite surface protein 4 of Plasmodium    falciparum. Mol Biochem Parasitol 2002, 120(2), 301-303.-   32 Jongwutiwes, S., Putaporntip, C., Friedman, R. & Hughes, A. L.    The Extent of Nucleotide Polymorphism is Highly Variable Across a    3-kb Region on Plasmodium falciparum Chromosome 2. Mol Biol Evol    2002, 19(9), 1585-1590.-   33 Polson, H. E., Conway, D. J., Fandeur, T., Mercereau-Puijalon, O.    & Longacre, S. Gene polymorphism of Plasmodium falciparum merozoite    surface proteins 4 and 5. Mol Biochem Parasitol 2005, 142(1),    110-115.-   34 Puentes, A. G., J. Vera, R. Oopez, R. Suarez, J. Rodriguez, L.    Curtidor, H. Sporozoite and Liver Stage Antigen Plasmodium    falciparum peptides bind specifically to human hepatocytes. Vaccine    2004, 22, 1150-1156.-   35 Hale, R. S. & Thompson, G. Codon optimization of the gene    encoding a domain from human type 1 neurofibromin protein results in    a threefold improvement in expression level in Escherichia coli.    Protein Expr Purif 1998, 12(2), 185-188.-   36 Longacre, S., Mendis, K. N. & David, P. H. Plasmodium vivax    merozoite surface protein 1 C-terminal recombinant proteins in    baculovirus. Mol Biochem Parasitol 1994, 64(2), 191-205.-   37 Nacer, A., Berry, L., Slomianny, C. & Mattei, D. Plasmodium    falciparum signal sequences: simply sequences or special signals?    Int J Parasitol 2001, 31(12), 1371-1379.-   38 Utsumi, T., Nakano, K., Funakoshi, T. et al., Vertical-scanning    mutagenesis of amino acids in a model N-myristoylation motif reveals    the major amino-terminal sequence requirements for protein    N-myristoylation. Eur J Biochem 2004, 271(4), 863-874.-   39 Resh, M. D. Fatty acylation of proteins: new insights into    membrane targeting of myristoylated and palmitoylated proteins.    Biochim Biophys Acta 1999, 1451(1), 1-16.-   40 Gunaratne, R. S., Sajid, M., Ling, I. T., Tripathi, R.,    Pachebat, J. A. & Holder, A. A. Characterization of    N-myristoyltransferase from Plasmodium falciparum. Biochem J 2000,    348 Pt 2, 459-463.-   41 Price, H. P., Menon, M. R., Panethymitaki, C., Goulding, D.,    McKean, P. G. & Smith, D. F. Myristoyl-CoA:protein    N-myristoyltransferase, an essential enzyme and potential drug    target in kinetoplastid parasites. J Biol Chem 2003, 278(9),    7206-7214.-   42 Stafford, W. H., Stockley, R. W., Ludbrook, S. B. & Holder, A. A.    Isolation, expression and characterization of the gene for an    ADP-ribosylation factor from the human malaria parasite, Plasmodium    falciparum. Eur J Biochem 1996, 242(1), 104-113.-   43 Stevenson, F. T., Bursten, S. L., Locksley, R. M. & Lovett, D. H.    Myristyl acylation of the tumor necrosis factor alpha precursor on    specific lysine residues. J Exp Med 1992, 176(4), 1053-1062.-   44 Farazi, T. A., Waksman, G. & Gordon, J. I. The biology and    enzymology of protein N-myristoylation. J Biol Chem 2001, 276(43),    39501-39504.-   45 Hayashi, N., Nakagawa, C., Ito, Y. et al.    Myristoylation-regulated direct interaction between calcium-bound    calmodulin and N-terminal region of pp 60v-src. J Mol Biol 2004,    338(1), 169-180.-   46 Maekawa, S., Matsuura, Y. & Nakamura, S. Expression and    myristoylation of NAP-22 using a baculovirus transfer vector system.    Biochim Biophys Acta 1994, 1218(1), 119-122.-   47 Perraut, R., Marrama, L., Diouf, B. et al. Distinct surrogate    markers for protection against Plasmodium falciparum infection and    clinical malaria identified in a Senegalese community after radical    drug cure. J Infect Dis 2003, 188(12), 1940-1950.-   48 Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. &    Seeberger, P. H. Synthetic GPI as a candidate anti-toxic vaccine in    a model of malaria. Nature 2002, 418(6899), 785-789.-   49 Bonnet S. et al, Vaccine 2006, vol. 24, p. 5997-6008, soluble and    glyco-lipid modified Baculovirus Plasmodium falciparum C-terminal    Merozoite Surface Protein 1, two forms of leading malaria vaccine    candidate.

1. A purified nucleic acid molecule comprising the DNA sequence of SEQID NOS: 1, 2, 3, 4, 5, 6, 7, 28, 29, or
 8. 2. A purified nucleic acidmolecule encoding an amino acid sequence comprising the sequence of SEQID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 30, or
 22. 3.A purified nucleic acid molecule that hybridizes to either strand of adenatured, double-stranded DNA comprising the nucleic acid sequence ofany one of claim 1 or 2 under conditions of moderate stringency in 50%formamide and 6×SSC, at 42° C. with washing conditions of 60° C.,0.5×SSC, 0.1% SDS.
 4. The purified nucleic acid molecule as claimed inclaim 3, wherein said isolated nucleic acid molecule is derived by invitro mutagenesis from SEQ ID NOS: 1-8.
 5. A purified nucleic acidmolecule degenerate from SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7 or 8 as aresult of the genetic code.
 6. A purified nucleic acid molecule, whichencodes recombinant MSP4 or MSP5 polypeptide, an allelic variant ofrecombinant MSP4 or MSP5 polypeptide DNA, or a homolog of recombinantMSP4 or MSP5 polypeptide DNA.
 7. A recombinant vector that directs theexpression of a nucleic acid molecule selected from the group consistingof the purified nucleic acid molecules of claims 1, 2, 5, and
 6. 8. Arecombinant vector that directs the expression of a nucleic acidmolecule of claim
 3. 9. A recombinant vector that directs the expressionof a nucleic acid molecule of claim
 4. 10. A purified polypeptideencoded by a nucleic acid molecule selected from the group consisting ofthe purified nucleic acid molecules of claims 1, 2, 5, and
 6. 11. Apurified polypeptide according to claim 10 in non-glycosylated form. 12.A purified polypeptide encoded by a nucleic acid molecule of claim 3.13. A purified polypeptide according to claim 12 in non-glycosylatedform.
 14. A purified polypeptide encoded by a nucleic acid molecule ofclaim
 4. 15. A purified polypeptide according to claim 14 innon-glycosylated form.
 16. Purified antibodies that bind to apolypeptide of claim
 10. 17. Purified antibodies according to claim 16,wherein the antibodies are monoclonal antibodies.
 18. Purifiedantibodies that bind to a polypeptide of claim
 12. 19. Purifiedantibodies according to claim 18, wherein the antibodies are monoclonalantibodies.
 20. Purified antibodies that bind to a polypeptide of claim14.
 21. Purified antibodies according to claim 20, wherein theantibodies are monoclonal antibodies.
 22. A host cell transfected,transduced or infected with the vector of claim
 7. 23. A method for theproduction of recombinant MSP4 or MSP5 polypeptide comprising culturinga host cell of claim 22 under conditions promoting expression, andrecovering the polypeptide from the culture medium.
 24. The method ofclaim 23, wherein the host cell is selected from the group consisting ofinsect cells, bacterial cells, yeast cells, plant cells, and animalcells.
 25. A host cell transfected, infected or transduced with thevector of claim
 8. 26. A method for the production of recombinant MSP4and MSP5 polypeptides comprising culturing a host cell of claim 25 underconditions promoting expression, and recovering the polypeptide from theculture medium or cellular pellets.
 27. The method of claim 26, whereinthe host cell is selected from the group consisting of insect cells,bacterial cells, yeast cells, plant cells, and animal cells.
 28. A hostcell transfected, infected or transduced with the vector of claim
 9. 29.A method for the production of recombinant MSP4 and MSP5 polypeptidecomprising culturing a host cell of claim 28 under conditions promotingexpression, and recovering the polypeptide from the culture medium orcellular aggregates.
 30. The method of claim 29, wherein the host cellis selected from the group consisting of insect cells, bacterial cells,yeast cells, plant cells, and animal cells.
 31. A recombinant vectorselected from the group consisting of 1-3512, I-3513, I-3514, I-3694,I-3695 and I-3696.
 32. An immunological complex comprising a recombinantMSP4 and MSP5 polypeptide and an antibody that specifically recognizessaid polypeptide.
 33. A method for detecting infection by malariaparasite, wherein the method comprises providing a compositioncomprising a biological material suspected of being infected withmalaria parasite, and assaying for the presence of native MSP4 and/orMSP5 polypeptide of malaria parasite that binds to an antibody specificfor recombinant MSP4 or MSP5 polypeptide.
 34. The method of claim 33,wherein it is used to detect Plasmodium falciparum.
 35. The method ofclaim 33, wherein it is used to detect Plasmodium vivax.
 36. The methodof claim 33, wherein the native MSP4 or MSP5 polypeptide is assayed byelectrophoresis or by immunoassay with antibodies that areimmunologically reactive with the recombinant MSP4 and MSP5 polypeptide.37. An in vitro diagnostic method for the detection of the presence orabsence of antibodies, which bind to an antigen comprising recombinantMSP4 or MSP5 polypeptide, wherein the method comprises contacting theantigen with a biological fluid for a time and under conditionssufficient for the antigen and antibodies in the biological fluid toform an antigen-antibody complex, and detecting the formation of thecomplex.
 38. The method of claim 35, which further comprises measuringthe formation of the antigen-antibody complex.
 39. The method of claim35, wherein the formation of antigen-antibody complex is detected byimmunoassay based on Western blot technique, ELISA, indirectimmunofluorescence assay, or immunoprecipitation assay.
 40. A diagnostickit for the detection of the presence or absence of antibodies, whichbind to recombinant MSP4 or MSP5 polypeptide or mixtures thereof,wherein the kit comprises an antigen comprising recombinant MSP4 or MSP5polypeptide or mixtures of recombinant MSP4 and MSP5 polypeptides, andmeans for detecting the formation of immune complex between the antigenand antibodies, wherein the means are present in an amount sufficient toperform said detection.
 41. An immunogenic composition comprising atleast one recombinant MSP4 or MSP5 polypeptide or a mixture thereof inan amount sufficient to induce an immunogenic or protective response invivo, and a pharmaceutically acceptable carrier therefore.
 42. Theimmunogenic composition of claim 41, wherein said composition comprisesa sufficient amount of at least one recombinant MSP4 or MSP5 polypeptideto induce neutralizing antibodies in vivo.
 43. The immunogeniccomposition of claim 41 comprising at least the recombinant polypeptideMSP4p40.
 44. The immunogenic composition of claim 41 comprising at leastthe recombinant polypeptide MSP4p30.
 45. The immunogenic composition ofclaim 41 comprising at least the recombinant polypeptide MSP4p20. 46.The immunogenic composition of claim 41 comprising at least therecombinant polypeptides MSP5p45 and MSP5p35.
 47. The immunogeniccomposition of claim 39 comprising at least the recombinant polypeptidePvMSP4p20.
 48. A polynucleotide selected from SEQ ID NO: 1, 2, 3, 4, 5,6, 7, or
 8. 49. A polynucleotide selected from SEQ ID NO: 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or
 30. 50. The immunogeniccomposition of claim 41 comprising at least a recombinant polypeptidechosen among PfMSP4p21ss1 and PfMSP4p21ss2.
 51. The immunogeniccomposition of claim 39 comprising at least the recombinant polypeptidesMSP4p40 and MSP4p20.
 52. The immunogenic composition of claim 39 furthercomprising an antigen comprising the recombinant MSP1p19 polypeptide.53. A vaccine composition comprising at least one recombinant MSP4 orMSP5 polypeptide or a mixture thereof in an amount sufficient to inducea protective response in vivo, and a pharmaceutically acceptable carriertherefore, wherein the at least one recombinant MSP4 or MSP5 polypeptideis chosen among MSP4p40, MSP4p30, MSP4p20, MSP4p21ss1, MSP4p21ss2,MSP5p45, MSP5p35 and PvMSP4p20.
 54. A method for in vitro diagnosing aPlasmodium infection in a sample of biological material from a humansuspected to be infected by the parasite, wherein the method comprisesthe following steps: contacting an antigen comprising recombinant MSP4or MSP5 polypeptide with the sample for a time and under conditionssufficient for the antigen and antibodies in the sample to form anantigen-antibody complex, and detecting the formation of the complex.55. The method as claimed in claim 54, which further comprises measuringthe formation of the antigen-antibody complex.
 56. The method as claimedin claim 54, wherein the formation of antigen-antibody complex isdetected by immunoassay based on Western blot technique, ELISA, indirectimmunofluorescence assay, or immunoprecipitation assay.
 57. The methodof claim 36, wherein the native MSP4 or MSP5 polypeptide is assayed byimmunoassay with antibodies secreted by hybridoma deposited at C.N.C.M.on Nov. 16, 2005 under Accession number I-3517, I-3518, I-3519 orI-3520.
 58. Purified antibodies according to claim 17, wherein they areproduced from hybridoma deposited at C.N.C.M. on Nov. 16, 2005 underAccession number I-3517, I-3518, I-3519 or I-3520
 59. Hybridomadeposited at C.N.C.M. on Nov. 16, 2005 under Accession number I-3517,I-3518, I-3519 or I-3520.
 60. A method for detecting a malaria parasite,wherein the method comprises providing a composition comprising abiological material suspected of being infected with malaria parasite,and assaying for the presence of native MSP4 and/or MSP5 polypeptide ofmalaria parasite that binds to an antibody specific for recombinant MSP4or MSP5 polypeptide or a mixture of at least one antibody specific forrecombinant MSP4 polypeptide and at least one antibody specific forrecombinant MSP5 polypeptide.
 61. The method of claim 60, wherein therecombinant MSP4 or MSp5 polypeptide is selected among the purifiedpolypeptides of claim
 10. 62. The method of claim 60, wherein theantibody specific for recombinant MSP4 or MSP5 polypeptide is selectedamong the purified antibodies of claim
 58. 63. The method of claim 60,wherein it is used to detect Plasmodium falciparum or Plasmodium vivax.